| sct_182833002 |
Concomitant medications? |
adverse_events_related_to_anticovid19_vaccine |
| sct_182833002_specify |
Concomitant medications - please, specify: |
adverse_events_related_to_anticovid19_vaccine |
| ln_8310_5 |
Body temperature measurement available? |
baseline_information |
| ln_8310_5_value |
Body temperature value |
baseline_information |
| ln_8462_4 |
Diastolic blood pressure measurement available? |
baseline_information |
| ln_8462_4_value |
Diastolic blood pressure value |
baseline_information |
| ln_8480_6 |
Systolic blood pressure measurement available? |
baseline_information |
| ln_8480_6_value |
Systolic blood pressure value |
baseline_information |
| ln_8867_4 |
Heart rate measurement available? |
baseline_information |
| ln_8867_4_value |
Heart rate value |
baseline_information |
| ln_9279_1 |
Respiratory rate measurement available? |
baseline_information |
| ln_9279_1_value |
Respiratory rate value |
baseline_information |
| sct_161663000_1 |
Affected organ: |
baseline_information |
| sct_363346000_1 |
Hemato - Oncologic disease: |
baseline_information |
| sct_438173002 |
PaO2 / FiO2 ratio |
biochemistry |
| ln_3173_2_avail |
Activated partial thromboplastin time (aPTT) available |
biochemistry |
| ln_3173_2_date |
Activated partial thromboplastin time (aPTT) date |
biochemistry |
| ln_3173_2 |
Activated partial thromboplastin time (aPTT)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_24336_0 |
Arterial blood gas test available? |
biochemistry |
| ln_24336_0_date |
Arterial blood gas test date |
biochemistry |
| ln_1959_6 |
BicarbonatesDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated.LP15441-6 Bicarbonate Bicarbonate is an electrolyte and typically measured along with other electrolytes (e.g. sodium, potassium, and chloride) to detect, evaluate, and monitor electrolyte imbalances. Low bicarbonate levels may occur in patients with Addison's disease, chronic diarrhea, diabetic ketoacidosis, and kidney disease. Increased levels may be seen in patients with severe vomiting, cushing syndrome, and metabolic alkalosis. Various drugs may also increase or decrease biocarbonate levels.[Lab Tests Online: co2]
LP15441-6 Bicarbonate Bicarbonate is an electrolyte and typically measured along with other electrolytes (e.g. sodium, potassium, and chloride) to detect, evaluate, and monitor electrolyte imbalances. Low bicarbonate levels may occur in patients with Addison's disease, chronic diarrhea, diabetic ketoacidosis, and kidney disease. Increased levels may be seen in patients with severe vomiting, cushing syndrome, and metabolic alkalosis. Various drugs may also increase or decrease biocarbonate levels.[Lab Tests Online: co2]
|
biochemistry |
| ln_42719_5_54363_7_avail |
Bilirubin available |
biochemistry |
| ln_42719_5_54363_7_date |
Bilirubin date |
biochemistry |
| ln_42719_5_54363_7_unit |
Bilirubin unit |
biochemistry |
| ln_42719_5_54363_7 |
BilirubinDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_89579_7_10839_9_avail |
Cardiac Troponin I availableLP14890-5 Troponin I.cardiac Troponin I is a part of the troponin complex. It binds to actin in thin myofilaments to hold the actin-tropomyosin complex in place. Because of it myosin cannot bind actin in relaxed muscle. When calcium binds to the Troponin C it causes conformational changes which lead to dislocation of troponin I and finally tropomyosin leaves the binding site for myosin on actin leading to contraction of muscle. The letter I is given due to its inhibitory character. |
biochemistry |
| ln_89579_7_10839_9_date |
Cardiac Troponin I date |
biochemistry |
| ln_89579_7_10839_9_unit |
Cardiac Troponin I unit |
biochemistry |
| ln_89579_7_10839_9 |
Cardiac Troponin IDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_48425_3_67151_1_avail |
Cardiac Troponin T availableLP17145-1 Troponin T.cardiac Troponin T is a part of the troponin complex. It binds to tropomyosin, interlocking them to form a troponin-tropomyosin complex. |
biochemistry |
| ln_48425_3_67151_1_date |
Cardiac Troponin T date |
biochemistry |
| ln_48425_3_67151_1_unit |
Cardiac Troponin T unit |
biochemistry |
| ln_48425_3_67151_1 |
Cardiac Troponin TDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| urine_test_concentration |
ConcentrationDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_1988_5_76485_2_avail |
C-reactive protein (CRP) available |
biochemistry |
| ln_1988_5_76485_2_date |
C-reactive protein (CRP) date |
biochemistry |
| ln_1988_5_76485_2_unit |
C-reactive protein (CRP) unit |
biochemistry |
| ln_1988_5_76485_2 |
C-reactive protein (CRP)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2157_6_avail |
Creatine kinase (CK) availableLP15510-8 Creatine kinase Creatine kinase (CK), also known as phosphocreatine kinase or creatine phosphokinase (CPK) is an enzyme expressed by various tissues. It catalyzes the conversion of creatine to phosphocreatine, consuming adenosine triphosphate (ATP) and generating adenosine diphosphate (ADP). In tissues that consume ATP rapidly, especially skeletal muscles, but also the brain and smooth muscles, creatine phosphate serves as an energy reservoir for the rapid regeneration of ATP, the major source of energy in biochemical reactions. |
biochemistry |
| ln_2157_6_date |
Creatine kinase (CK) date |
biochemistry |
| ln_2157_6_unit |
Creatine kinase (CK) unit |
biochemistry |
| ln_2157_6 |
Creatine kinase (CK)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2160_0_14682_9_avail |
Creatinine availableLP14355-9 Creatinine Creatinine or creatine anhydride, is a breakdown product of creatine phosphate in muscle. The loss of water molecule from creatine results in the formation of creatinine. It is transferred to the kidneys by blood plasma, whereupon it is eliminated by glomular filtration and partial tubular excretion. Creatinine is usually produced at a fairly constant rate and measuring its serum level is a simple test. A rise in blood creatinine levels is observed only with marked damage to functioning nephrons; therefore this test is not suitable for detecting early kidney disease. Creatine and creatinine are metabolized in the kidneys, muscle, liver and pancreas. |
biochemistry |
| ln_2160_0_14682_9_date |
Creatinine date |
biochemistry |
| ln_2160_0_14682_9_unit |
Creatinine unit |
biochemistry |
| ln_2160_0_14682_9 |
CreatinineDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| sct_703503000_17 |
Data collector - Biochemistry |
biochemistry |
| sct_399651003_17 |
Date of collection - Biochemistry |
biochemistry |
| ln_91556_1_avail |
D-dimer available |
biochemistry |
| ln_915506_1_date |
D-dimer date |
biochemistry |
| ln_91556_1_unit |
D-dimer unit |
biochemistry |
| ln_91556_1 |
D-dimerDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_33051_4 |
Erythrocytes (qualitative)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2276_4_14723_1_avail |
Ferritin available |
biochemistry |
| ln_2276_4_14723_1_date |
Ferritin date |
biochemistry |
| ln_2276_4_14723_1_unit |
Ferritin unit |
biochemistry |
| ln_2276_4_14723_1 |
FerritinDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_48664_7_3255_7_avail |
Fibrinogen available |
biochemistry |
| ln_48664_7_3255_7_date |
Fibrinogen date |
biochemistry |
| ln_48664_7_3255_7_unit |
Fibrinogen unit |
biochemistry |
| ln_48664_7_3255_7 |
FibrinogenDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2324_2_avail |
Gamma glutamyl transpeptidase (GGT) availableLP15590-0 Gamma glutamyl transferase Gamma glutamyl transferase (GGT or GGTP, or Gamma-GT) is a liver enzyme. It is involved in the transfer of amino acids across the cellular membrane and in glutathione metabolism. GGT is found in high concentrations in the liver, bile ducts and kidney. The enzyme is also present in other tissues, such as the epididymis. Its level in the blood may be tested because if it is elevated this may indicate an abnormality in the liver, though this can be caused by a number of conditions including: congestive heart failure, cholestasis (congestion of the bile ducts), cirrhosis of the liver, necrosis of the liver. Levels of GGT are also increased in chronic and acute alcohol abuse. |
biochemistry |
| ln_2324_2_date |
Gamma glutamyl transpeptidase (GGT) date |
biochemistry |
| ln_2324_2 |
Gamma glutamyl transpeptidase (GGT)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2349_9 |
Glucose (qualitative)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2345_7_72516_8_avail |
Glucose available |
biochemistry |
| ln_2345_7_72516_8_date |
Glucose date |
biochemistry |
| ln_2345_7_72516_8_unit |
Glucose unit |
biochemistry |
| ln_2345_7_72516_8 |
GlucoseDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_1920_8_avail |
Glutamat-Oxalacetat-Transaminase / Aspartat-Aminotransferase (GOT/AST) available |
biochemistry |
| ln_1920_8_date |
Glutamat-Oxalacetat-Transaminase / Aspartat-Aminotransferase (GOT/AST) date |
biochemistry |
| ln_76625_3_avail |
Glutamat-Pyruvat-Transaminase / Alanine-aminotransferase (GTP/ALT) availableLP15333-5 Alanine aminotransferase Alanine transaminase or ALT is an enzyme (EC 2.6.1.2) also called serum glutamic pyruvic transaminase (SGPT) or alanine aminotransferase (ALAT). It is found in serum and in various bodily tissues, but is most commonly associated with the liver. It catalyzes the two parts of the alanine cycle. It is commonly measured clinically as a part of a diagnostic evaluation of liver health. Significantly elevated levels of ALT often suggest the existence of other medical problems such as viral hepatitis, diabetes, congestive heart failure, bile duct problems, infectious mononucleosis, or myopathy. However, elevated levels of ALT do not automatically mean that medical problems exist. Fluctuation of ALT levels is normal over the course of the day, and ALT levels can also increase in response to strenuous physical exercise. |
biochemistry |
| ln_76625_3_date |
Glutamat-Pyruvat-Transaminase / Alanine-aminotransferase (GTP/ALT) date |
biochemistry |
| ln_59261_8_4548_4_avail |
Haemoglobin A1c (Hb A1c) availableLP16413-4 Hemoglobin A1c Currently (2010), four standardization protocols exist for measuring Hgb A1c:
1. IFCC - designated as a Reference Method or RM (http://www.ifcchba1c.net/)
2. NGSP - the long standing protocol used in the US and most other countries since the DCCT study (http://www.ngsp.org/factors.asp)
3.JDS/JSCC - a protocol used in Japan, Spain and possibly other countries
4. Swedish - used in Sweden at least
Protocols 2-4 are known as Designated Comparison Methods (DCM) and have been connected to the Reference Method and each other through various regression equations.
Because of the high degrees of standardization within protocol it should no longer be necessary to specify a LOINC code with a method such as "HPLC", "electrophoresis" or anything else. Analytical instruments will be designed so that an Hgb A1c result can be traced back to a specific standardization protocol, so the important distinction will be the standardization protocol as described above and which will be carried in the method field.
A meeting of instrument manufacturers (presumably including Japanese) in Milan, Italy, December 12, 2007, agreed (among other items) that:
-All manufacturers should implement worldwide the traceability to the IFCC reference system for Hgb -A1c.
-All new instruments sold after January 1st, 2011 will report (as a result of an Hgb A1c test) both SI (mmol/mol - no decimals) and NGSP derived units (percentage - one decimal), in agreement with the Consensus Statement.
-Note they only committed to supporting protocol (1) and (2)
Different countries are adopting the international harmonization recommendations in different ways. We have information from the NGSP that the US will continue to report only Hgb A1c/NGSP, with the unit percent - i.e., no change. In Great Britain, labs have already started to report all results both as Hgb A1c (NGSP) in % and Hgb A1c (IFCC) in mmol/mol. In Canada, they are awaiting a recommendation from an expert panel. Any of these measures could be reported in the same units, but the convention for the reporting Hgb A1c under the new IFCC protocol will be to use units of mmol/mol to avoid confusion between the DCCT/NGSP and the IFFCC protocol.
LOINC has defined 59261-8 (Hemoglobin A1c/Hemoglobin.total in Blood) by IFCC protocol.
These protocols produce different results when expressed in the same units. For example, the equivalent of Hgb A1c (NGSP) of 6.5% is Hgb A1c (IFCC) is 4.8%.
The NGSP web site (http://www.ngsp.org/factors.asp) suggests the use of alternate measures, such as glycated albumen, for patients with severe iron deficiency, dialysis patients, and those with SS SC CC because of over or under reading that can occur with these interferences. It also describes the effect of abnormal hemoglobins on results of HbA1c by instrument.
|
biochemistry |
| ln_59261_8_4548_4_date |
Haemoglobin A1c (Hb A1c) date |
biochemistry |
| sct_396550006 |
Has a blood test been performed? |
biochemistry |
| ln_59261_8_4548_4_unit |
Hemoglobin A1c (Hb A1c) unit |
biochemistry |
| ln_59261_8_4548_4 |
Hemoglobin A1c (Hb A1c)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_3150_0_biochemistry |
Inspiratory oxygen fraction (FiO2)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_34714_6_avail |
International normalized ratio (INR) available |
biochemistry |
| ln_34714_6_date |
International normalized ratio (INR) date |
biochemistry |
| ln_34714_6 |
International normalized ratio (INR)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_33052_2_ql |
Leukocytes (qualitative)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_731_0_26474_7_26478_8_a |
Lymphocytes available |
biochemistry |
| ln_731_0_26474_7_26478_8_d |
Lymphocytes date |
biochemistry |
| ln_731_0_26474_7_26478_8_u |
Lymphocytes unit |
biochemistry |
| ln_731_0_26474_7_26478_8 |
LymphocytesDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_26499_4_93352_3_avail |
Neutrophiles availableLP14267-6 Neutrophils Neutrophils are the most common form of white blood cells in healthy adults. Neutrophils are approximately 13 micrometers in diameter and have segmented nuclei with 3-5 lobes that are connected by thin strands of chromatin. (Practical Haematology; Barbara J. Bain, Imelda Bates, Mike A. Laffan,S. Mitchell Lewis; Eleventh edition; 2012) Neutrophils function to fight infection by both engulfing microorganisms and secreting lethal enzymes.
|
biochemistry |
| ln_26499_4_93352_3_date |
Neutrophiles date |
biochemistry |
| ln_26499_4_93352_3 |
Neutrophiles unit |
biochemistry |
| ln_26499_4_93352_3_unit |
NeutrophilesDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_33762_6_avail |
N-terminal B-type natriuretic peptide (NT-pro-BNP) available |
biochemistry |
| ln_33762_6_date |
N-terminal B-type natriuretic peptide (NT-pro-BNP) date |
biochemistry |
| ln_33762_6 |
N-terminal B-type natriuretic peptide (NT-pro-BNP)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_11557_6_unit |
Partial carbon dioxide pressure (PaCO2) Unit |
biochemistry |
| ln_11557_6 |
Partial carbon dioxode pressure (PaCO2)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_11556_8_unit |
Partial oxygen pressure (PaO2) Unit |
biochemistry |
| ln_11556_8 |
Partial oxygen pressure (PaO2)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_11558_4 |
pH valueDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated.::LP14752-7 pH pH is a measure of the acidity or basicity of a solution. It is defined as the cologarithm of dissolved hydrogen ions (H+). Hydrogen ion activity coefficients cannot be measured experimentally, so they are based on theoretical calculations. The pH scale is not an absolute one, it is relative to a set of internationally established standard solutions. pH 7.0 is considered neutral. |
biochemistry |
| ln_2756_5 |
pH valueDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated.::LP14752-7 pH pH is a measure of the acidity or basicity of a solution. It is defined as the cologarithm of dissolved hydrogen ions (H+). Hydrogen ion activity coefficients cannot be measured experimentally, so they are based on theoretical calculations. The pH scale is not an absolute one, it is relative to a set of internationally established standard solutions. pH 7.0 is considered neutral. |
biochemistry |
| ln_77142_8_avail |
Potassium (K+) availableLP15098-4 Potassium Potassium (symbol K from Latin:kalium) is a key chemical element involved in neuron function and influencing osmotic balance between cells and interstitial fluid. Depletion in potassium levels results in deficient fluid and electrolyte balance in the body as well as various nervous and cardiac dysfunctions. Studies suggest diets high in potassium can reduce the risk of hypertension and possibly stroke. Foods rich in potassium include parsley, dried apricots, potatoes, bananas, avocados, soybeans, and bran, as well as most fruits, vegetables, meat and fish. Overall, clear cases of potassium deficiency are rare in healthy individuals. |
biochemistry |
| ln_77142_8_date |
Potassium (K+) date |
biochemistry |
| ln_77142_8_unit |
Potassium (K+) unit |
biochemistry |
| ln_77142_8 |
Potassium (K+)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_33959_8_avail |
Procalcitonin (PCT) availableLP31682-5 Procalcitonin Procalcitonin (PCT) is a precursor of the hormone calcitonin, which is involved with calcium homeostasis, and is produced by the C-cells of the thyroid gland. It is there that procalcitonin is cleaved into calcitonin, katacalcin and a protein residue. It is not released into the blood stream of healthy individuals. With the derangements that a severe infection with an associated systemic response brings, the blood levels of procalcitonin may rise to 100 ng/ml. In blood serum, procalcitonin has a half-life of 25 to 30 hours. |
biochemistry |
| ln_33959_8_date |
Procalcitonin (PCT) date |
biochemistry |
| ln_33959_8 |
Procalcitonin (PCT)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2887_8 |
Proteins (qualitative)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated.LP15838-3 Protein Protein testing is performed to evaluate and monitor liver and kidney function and to detect and diagnose early kidney damage and various other diseases. Elevated protein levels may also be due to an infection, medication, vigorous exercise, or emotional or physical stress. Body fluids contain many different proteins that serve diverse functions such as transport of nutrients, removal of toxins, control of metabolic processes, and defense against invaders. Testing for protein levels may be done as part of a routine physical, a pregnancy workup, in cased of a suspected UTI, as part of a hospital admission, or to evaluate kidney function. |
biochemistry |
| ln_76631_1_54347_0_1751_7a |
Serum-Albumin available |
biochemistry |
| ln_76631_1_54347_0_1751_7d |
Serum-Albumin date |
biochemistry |
| ln_76631_1_54347_0_1751_7u |
Serum-Albumin unit |
biochemistry |
| ln_76631_1_54347_0_1751_7 |
Serum-AlbuminDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_2951_2_avail |
Sodium (Na+) available |
biochemistry |
| ln_2951_2_date |
Sodium (Na+) date |
biochemistry |
| ln_2951_2_unit |
Sodium (Na+) unit |
biochemistry |
| ln_2951_2 |
Sodium (Na+)During the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| ln_26515_7_avail |
Thrombocytes available |
biochemistry |
| ln_26515_7_date |
Thrombocytes date |
biochemistry |
| ln_26515_7_unit |
Thrombocytes unit |
biochemistry |
| ln_26515_7 |
ThrombocytesDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| urine_tests_date |
Urine tests date |
biochemistry |
| ln_2519_7_30241_4_avail |
Venous lactate available |
biochemistry |
| ln_2519_7_30241_4_date |
Venous lactate date |
biochemistry |
| ln_2519_7_30241_4_unit |
Venous lactate unit |
biochemistry |
| ln_2519_7_30241_4 |
Venous lactateDuring the SARS-CoV-2 infection register the first blood analysis available.In the follow-up visit reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
biochemistry |
| urine_tests_performed |
Were urine tests performed? |
biochemistry |
| ln_29463_7 |
Body weight value |
biometric_parameters |
| ln_29463_7_avail |
Body weight measurement available? |
biometric_parameters |
| ln_29463_7_unit |
Unit used to measure body weight |
biometric_parameters |
| ln_39156_5 |
Body Mass Index (kg, cm) |
biometric_parameters |
| ln_39156_5_lb_inch |
Body Mass Index (lb, in) |
biometric_parameters |
| ln_8302_2 |
Body height value |
biometric_parameters |
| ln_8302_2_avail |
Body height measurement available? |
biometric_parameters |
| ln_8302_2_unit |
Unit used to measure body height |
biometric_parameters |
| sct_363346000_type |
Active tumor/cancer disease description |
new_medical_events |
| sct_197270009 |
Acute liver dysfunction since the last visit No changes means stable disease |
new_medical_events |
| sct_40095003_14669001 |
Acute renal injury / acute renal failure since the last visit No changes means stable disease |
new_medical_events |
| sct_408229005 |
CD19+ cells (in %) |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_408229005_v2 |
CD19+ cells (in %) |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_313812005 |
CD3+ cells (in %) |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_313812005_v2 |
CD3+ cells (in %) |
cellular_immunity_analysis_2_pbmcs_2 |
| ln_20603_7 |
CD38+ cells (in %)LP17755-7 Cells.CD38 CD38 (cluster of differentiation 38) is a glycoprotein found on the surface of many immune cells (white blood cells), including CD4+, CD8+, B and natural killer cells. It is a marker of cell activation. The CD38 protein has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism, as well as some genetically determined conditions. It has also been used as a prognostic marker in leukemia. The gene encoding for CD38 is located on chromosome 4. CD38 is a novel multifunctional ectoenzyme widely expressed in cells and tissues especially in leukocytes. CD38 also functions in cell adhesion, signal transduction and calcium signaling.
CD34 is found on hematopoietic stem cells (HSC) as well as many of the more differentiated cells that CD38 is found on, so one method for isolating HSC cells is by selecting for cells that express CD34 but do not express CD38. |
cellular_immunity_analysis_1_pbmcs_1 |
| ln_20603_7_v2 |
CD38+ cells (in %) |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_313938009 |
CD4+ cells (in %) |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_313938009_v2 |
CD4+ cells (in %) |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_391438002 |
CD45+ cells (in %) |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_391438002_v2 |
CD45+ cells (in %) |
cellular_immunity_analysis_2_pbmcs_2 |
| ln_45268_0_date |
Cellular immunity analysis - date of sample collection |
cellular_immunity_analysis_1_pbmcs_1 |
| ln_45268_0_date_v2 |
Cellular immunity analysis - date of sample collection |
cellular_immunity_analysis_2_pbmcs_2 |
| ln_45268_0_id |
Cellular immunity ORCHESTRA sample ID |
cellular_immunity_analysis_1_pbmcs_1 |
| ln_45268_0_id_v2 |
Cellular immunity ORCHESTRA sample ID |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_703503000_21 |
Data collector - Cellular Immunity Analysis |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_703503000_21_v2 |
Data collector - Cellular Immunity Analysis |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_399651003_21 |
Date of collection - Cellular Immunity Analysis |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_399651003_21_v2 |
Date of collection - Cellular Immunity Analysis |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_428933002_ifng_date |
ELISPOT-IFNg date |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_428933002_ifng_date_v2 |
ELISPOT-IFNg date |
cellular_immunity_analysis_pbmc_104022022_2 |
| sct_428933002_ifng |
ELISPOT-IFNg performed? |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_428933002_ifng_v2 |
ELISPOT-IFNg performed? |
cellular_immunity_analysis_pbmc_104022022_2 |
| sct_428933002_ifng_ql |
ELISPOT-IFNg result (qualitative) |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_428933002_ifng_ql_v2 |
ELISPOT-IFNg result (qualitative) |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_428933002_ifng_qn |
ELISPOT-IFNg result (quantitative) |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_428933002_ifng_qn_v2 |
ELISPOT-IFNg result (quantitative) |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_428933002_ifng_test |
ELISPOT-IFNg test - assay used |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_428933002_ifng_test_v2 |
ELISPOT-IFNg test - assay used |
cellular_immunity_analysis_2_pbmcs_2 |
| flow_cytometry_foxp3 |
FOXP3+ cells (in %) |
cellular_immunity_analysis_1_pbmcs_1 |
| flow_cytometry_foxp3_v2 |
FOXP3+ cells (in %) |
cellular_immunity_analysis_2_pbmcs_2 |
| ln_45268_0 |
Has a sample for cellular immunity analysis been collected? |
cellular_immunity_analysis_1_pbmcs_1 |
| ln_45268_0_v2 |
Has a sample for cellular immunity analysis been collected? |
cellular_immunity_analysis_2_pbmcs_2 |
| ln_29593_1 |
Ki-67+ cells (in %) |
cellular_immunity_analysis_1_pbmcs_1 |
| ln_29593_1_v2 |
Ki-67+ cells (in %) |
cellular_immunity_analysis_2_pbmcs_2 |
| ln_45268_0_ship |
Was the cellular immunity analysis performed locally or the sample shipped to WP6 laboratory? |
cellular_immunity_analysis_1_pbmcs_1 |
| ln_45268_0_ship_v2 |
Was the cellular immunity analysis performed locally or the sample shipped to WP6 laboratory? |
cellular_immunity_analysis_2_pbmcs_2 |
| sct_428933002_ifng_ship |
Was the ELISPOT-IFNg test performed locally or the sample shipped to WP6 laboratory? |
cellular_immunity_analysis_1_pbmcs_1 |
| sct_428933002_ifng_ship_v2 |
Was the ELISPOT-IFNg test performed locally or the sample shipped to WP6 laboratory? |
cellular_immunity_analysis_pbmc_104022022_2 |
| ln_30525_0 |
Age:
|
comorbidities |
| sct_118940003 |
Any neurological illness: |
comorbidities |
| sct_328383001_specify |
Liver disease (not hepatitis): |
comorbidities |
| sct_709044004 |
Chronic renal/kidney disease: |
comorbidities |
| sct_73211009_1 |
Does the patient suffer from diabetes? |
comorbidities |
| sct_85828009 |
Any rheumatological / autoimmune disease: |
comorbidities |
| sct_85828009_other |
Other rheumatological / autoimmune disease - please, specify: |
comorbidities |
| sct_85828009_specify |
Any rheumatological / autoimmune disease - please, specify: |
comorbidities |
| sct_86406008 |
Is the patient infected with HIV? |
comorbidities |
| icu_admission_date |
Intensive care unit admission date |
covid19_admission |
| icu_discharge_date |
Intensive care unit discharge date |
covid19_admission |
| sct_184305005_2 |
Cause of death (specify) |
covid19_admission |
| sct_305351004 |
Intensive care unit admission |
covid19_admission |
| sct_306685000 |
Discharged from acute hospital to an rehabilitation clinic |
covid19_admission |
| sct_32485007 |
Acute hospital admission |
covid19_admission |
| sct_371827001 |
Discharged alive |
covid19_admission |
| sct_398447004 |
Type of Covid-19 infection |
covid19_admission |
| sct_399423000 |
Acute hospital admission date |
covid19_admission |
| sct_399651003_8 |
Date of collection - Admission |
covid19_admission |
| sct_399753006_2 |
Date of death |
covid19_admission |
| sct_442864001 |
Acute hospital discharge date |
covid19_admission |
| sct_703503000_8 |
Data collector - Admission |
covid19_admission |
| events_cardiac |
Cardiac events During hospitalization or 30 days after diagnosis |
covid19_complications |
| sct_703503000_13 |
Data collector - COVID-19 complications |
covid19_complications |
| sct_399651003_13 |
Date of collection - COVID-19 complications |
covid19_complications |
| events_embolic |
Embolic events During hospitalization or 30 days after diagnosis |
covid19_complications |
| events_gastrointestinal |
Gastrointestinal events During hospitalization or 30 days after diagnosis |
covid19_complications |
| events_neurological |
Neurological eventsDuring hospitalization or 30 days after diagnosis |
covid19_complications |
| events_other_specify |
Other Covid-19 complications - specifyDuring hospitalization or 30 days after diagnosis |
covid19_complications |
| events_pulmonary |
Pulmonary events During hospitalization or 30 days after diagnosis |
covid19_complications |
| events_renal |
Renal events During hospitalization or 30 days after diagnosis |
covid19_complications |
| follow_up_date |
Date of follow-up visit |
covid19_outcome |
| sarscov2_re_infection |
SARS-CoV-2 re-infection since the last visit |
covid19_outcome |
| sct_184305005 |
Cause of death (specify) |
covid19_outcome |
| sct_399651003_6 |
Date of collection - Outcome |
covid19_outcome |
| sct_399753006 |
Date of death |
covid19_outcome |
| sct_438949009 |
Is the patient alive? |
covid19_outcome |
| sct_703503000_6 |
Data collector - Outcome |
covid19_outcome |
| ln_97852_8 |
WHO Clinical Progression Scale |
covid19_severity |
| ln_97852_8_avail |
WHO Clinical Progression Scale performed |
covid19_severity |
| ln_97852_8_date |
WHO Clinical Progression Scale date |
covid19_severity |
| sct_399651003_12 |
Date of collection - COVID-19 severity |
covid19_severity |
| sct_703503000_12 |
Data collector - COVID-19 severity |
covid19_severity |
| who_scale_score |
WHO Clinical Progression Scale score |
covid19_severity |
| sct_21522001_end |
Abdominal pain end date |
covid19_symptoms |
| sct_21522001_start |
Abdominal pain start date |
covid19_symptoms |
| sct_40917007_end |
Altered consciousness and/or confusion end date |
covid19_symptoms |
| sct_40917007_start |
Altered consciousness and/or confusion start date |
covid19_symptoms |
| sct_10325006_end |
Anomia end date |
covid19_symptoms |
| sct_10325006_start |
Anomia start date |
covid19_symptoms |
| sct_249468005_end |
Anorexia end date |
covid19_symptoms |
| sct_249468005_start |
Anorexia start date |
covid19_symptoms |
| sct_87486003_end |
Aphasia end date |
covid19_symptoms |
| sct_87486003_start |
Aphasia start date |
covid19_symptoms |
| sct_131148009_end |
Bleeding (haemorrhage) end date |
covid19_symptoms |
| sct_131148009_site |
Bleeding (haemorrhage) site |
covid19_symptoms |
| sct_131148009_start |
Bleeding (haemorrhage) start date |
covid19_symptoms |
| sct_36955009_271801002_en |
Changes or loss in taste (ageusia or dysgeusia) end date |
covid19_symptoms |
| sct_36955009_271801002_st |
Changes or loss in taste (ageusia or dysgeusia) start date |
covid19_symptoms |
| sct_29857009_23924001_end |
Chest pain and/or chest tightness end date |
covid19_symptoms |
| sct_29857009_23924001_star |
Chest pain and/or chest tightness start date |
covid19_symptoms |
| sct_9826008_end |
Conjunctivitis end date |
covid19_symptoms |
| sct_9826008_start |
Conjunctivitis start date |
covid19_symptoms |
| sct_49727002_end |
Cough end date |
covid19_symptoms |
| sct_49727002_start |
Cough start date |
covid19_symptoms |
| sct_703503000_9 |
Data collector - Symptoms |
covid19_symptoms |
| sct_399651003_9 |
Date of collection - Symptoms |
covid19_symptoms |
| sct_49727002_type |
Describe the cough |
covid19_symptoms |
| sct_49727002_sputum |
Describe the sputum |
covid19_symptoms |
| sct_62315008_end |
Diarrhea end date |
covid19_symptoms |
| sct_62315008_start |
Diarrhea start date |
covid19_symptoms |
| sct_271594007_end |
Fainting (syncopal episodes) end date |
covid19_symptoms |
| sct_271594007_start |
Fainting (syncopal episodes) start date |
covid19_symptoms |
| sct_84229001_367391008_end |
Fatigue and/or malaise end date |
covid19_symptoms |
| sct_84229001_367391008_sta |
Fatigue and/or malaise start date |
covid19_symptoms |
| sct_248427009_end |
Fever end date |
covid19_symptoms |
| sct_248427009_start |
Fever start date |
covid19_symptoms |
| sct_49727002 |
Has the patient had or does he/she currently have a cough?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_248427009 |
Has the patient had or does he/she currently have a fever?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_64531003 |
Has the patient had or does he/she currently have a runny nose (rhinorrhea)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_271807003 |
Has the patient had or does he/she currently have a skin rash?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_267102003 |
Has the patient had or does he/she currently have a sore throat?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_21522001 |
Has the patient had or does he/she currently have abdominal pain?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_40917007 |
Has the patient had or does he/she currently have altered consciousness and/or confusion?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_282145008 |
Has the patient had or does he/she currently have an inability to walk?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_10325006 |
Has the patient had or does he/she currently have anomia?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_249468005 |
Has the patient had or does he/she currently have anorexia?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| test_symptoms |
Has the patient had or does he/she currently have any of this symptoms?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| ln_75325_1 |
Has the patient had or does he/she currently have any symptoms? During the SARS-CoV-2 infection for the Covid-19 primary infectionOROngoing since primary Covid-19 infection or appearing since the last follow-up visit for any of the subsequent follow up visits |
covid19_symptoms |
| sct_249497008_422587007 |
Has the patient had or does he/she currently have any vomiting and/or nausea?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_87486003 |
Has the patient had or does he/she currently have aphasia?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_131148009 |
Has the patient had or does he/she currently have bleeding (haemorrhage)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_36955009_271801002 |
Has the patient had or does he/she currently have changes or loss in taste (ageusia or dysgeusia)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_29857009_23924001 |
Has the patient had or does he/she currently have chest pain and/or chest tightness?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_9826008 |
Has the patient had or does he/she currently have conjunctivitis?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_62315008 |
Has the patient had or does he/she currently have diarrhea?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_271594007 |
Has the patient had or does he/she currently have fainting (syncopal episodes)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_84229001_367391008 |
Has the patient had or does he/she currently have fatigue and/or malaise?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_25064002 |
Has the patient had or does he/she currently have headaches?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_57676002 |
Has the patient had or does he/she currently have joint pain (arthralgia)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_44169009 |
Has the patient had or does he/she currently have loss of sense of smell (anosmia)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| chestwall_indrawn |
Has the patient had or does he/she currently have lower chest wall indrawing?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_30746006 |
Has the patient had or does he/she currently have lymphadenopathy?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_48167000 |
Has the patient had or does he/she currently have memory loss?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_68962001 |
Has the patient had or does he/she currently have muscle pain (myalgia)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_68235000 |
Has the patient had or does he/she currently have nasal congestion?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_91175000 |
Has the patient had or does he/she currently have seizures?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_267036007 |
Has the patient had or does he/she currently have shortness of breath (dyspnea)?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_56018004 |
Has the patient had or does he/she currently have wheezing?During the SARS-CoV-2 infection or since the last follow-up visit |
covid19_symptoms |
| sct_25064002_end |
Headache end date |
covid19_symptoms |
| sct_25064002_start |
Headache start date |
covid19_symptoms |
| sct_282145008_end |
Inability to walk end date |
covid19_symptoms |
| sct_282145008_start |
Inability to walk start date |
covid19_symptoms |
| sct_57676002_end |
Joint pain (arthralgia) end date |
covid19_symptoms |
| sct_57676002_start |
Joint pain (arthralgia) start date |
covid19_symptoms |
| sct_44169009_end |
Loss of sense of smell (anosmia) end date |
covid19_symptoms |
| sct_44169009_start |
Loss of sense of smell (anosmia) start date |
covid19_symptoms |
| chestwall_indrawn_end |
Lower chest wall indrawing end date |
covid19_symptoms |
| chestwall_indrawn_start |
Lower chest wall indrawing start date |
covid19_symptoms |
| sct_30746006_end |
Lymphadenopathy end date |
covid19_symptoms |
| sct_30746006_start |
Lymphadenopathy start date |
covid19_symptoms |
| sct_48167000_end |
Memory loss end date |
covid19_symptoms |
| sct_48167000_start |
Memory loss start date |
covid19_symptoms |
| sct_68962001_end |
Muscle pain (myalgia) end date |
covid19_symptoms |
| sct_68962001_start |
Muscle pain (myalgia) start date |
covid19_symptoms |
| sct_68235000_end |
Nasal congestion end date |
covid19_symptoms |
| sct_68235000_start |
Nasal congestion start date |
covid19_symptoms |
| sct_64531003_end |
Runny nose (rhinorrhea) end date |
covid19_symptoms |
| sct_64531003_start |
Runny nose (rhinorrhea) start date |
covid19_symptoms |
| sct_91175000_end |
Seizures end date |
covid19_symptoms |
| sct_91175000_start |
Seizures start date |
covid19_symptoms |
| sct_267036007_end |
Shortness of breath (dyspnea) end date |
covid19_symptoms |
| sct_267036007_start |
Shortness of breath (dyspnea) start date |
covid19_symptoms |
| sct_271807003_end |
Skin rash end date |
covid19_symptoms |
| sct_271807003_start |
Skin rash start date |
covid19_symptoms |
| sct_267102003_end |
Sore throat end date |
covid19_symptoms |
| sct_267102003_start |
Sore throat start date |
covid19_symptoms |
| sct_249497008_422587007_en |
Vomiting and/or nausea end date |
covid19_symptoms |
| sct_249497008_422587007_st |
Vomiting and/or nausea start date |
covid19_symptoms |
| sct_56018004_end |
Wheezing end date |
covid19_symptoms |
| sct_56018004_start |
Wheezing start date |
covid19_symptoms |
| sct_182764009_end_date_6 |
[new_anticoag_specify] end date |
covid19_treatment |
| sct_182764009_start_date_2 |
[new_anticoag_specify] start date |
covid19_treatment |
| atc_l01xc_4_date |
[new_monocl_specify] administration date |
covid19_treatment |
| sct_788751009_route |
[sct_304275008_other] administration route |
covid19_treatment |
| sct_304275008_dose |
[sct_304275008_other] highest mg/day used |
covid19_treatment |
| sct_788751009_start |
[sct_304275008_other] start date |
covid19_treatment |
| sct_788751009_end |
[sct_304275008_other]end dateInclude ONLY the time period before steroids descalation |
covid19_treatment |
| sct_372558009_end |
[sct_372558009_specify] end date |
covid19_treatment |
| sct_372558009_start |
[sct_372558009_specify] start date |
covid19_treatment |
| sct_771452004_end |
[sct_771452004_specify] end date |
covid19_treatment |
| sct_771452004_start |
[sct_771452004_specify] start date |
covid19_treatment |
| sct_788081006_end |
[sct_788081006_other] end date |
covid19_treatment |
| sct_788081006_start |
[sct_788081006_other] start date |
covid19_treatment |
| therapy_other_end |
[therapy_other_specify] end date |
covid19_treatment |
| therapy_other_start |
[therapy_other_specify] start date |
covid19_treatment |
| l01el02_end |
Acalabrutinib end date |
covid19_treatment |
| l01el02_start |
Acalabrutinib start date |
covid19_treatment |
| l04ab04_end |
Adalimumab end date |
covid19_treatment |
| l04ab04_start |
Adalimumab start date |
covid19_treatment |
| l04ac03_end |
Anakinra end date |
covid19_treatment |
| l04ac03_start |
Anakinra start date |
covid19_treatment |
| sct_372733002_end |
Angiotensin converting enzyme inhibitor end date |
covid19_treatment |
| sct_372733002_start |
Angiotensin converting enzyme inhibitor start date |
covid19_treatment |
| sct_372913009_end2 |
Angiotensin II receptor antagonist end date |
covid19_treatment |
| sct_372913009_start2 |
Angiotensin II receptor antagonist start date |
covid19_treatment |
| sct_281789004_end |
Antibiotic therapy end date |
covid19_treatment |
| sct_281789004_start |
Antibiotic therapy start date |
covid19_treatment |
| sct_281789004 |
Antibiotic therapy used |
covid19_treatment |
| sct_372862008 |
Anticoagulants used Means therapy used with the purpose of Covid-19 treatmentIntermediate dose corresponds to a dose between normal prophylaxis and treatment dose |
covid19_treatment |
| sct_718526003 |
Antifungal agent used |
covid19_treatment |
| sct_788081006 |
Antiviral agent usedMeans therapy used with the purpose of Covid-19 treatment |
covid19_treatment |
| b01ac06_end |
Aspirin end date |
covid19_treatment |
| b01ac06_start |
Aspirin start date |
covid19_treatment |
| j05ae08_end |
Atazanavir end date |
covid19_treatment |
| j05ae08_start |
Atazanavir start date |
covid19_treatment |
| j01fa10_end |
Azithromycin end date |
covid19_treatment |
| j01fa10_start |
Azithromycin start date |
covid19_treatment |
| sct_1119336002_date |
Bamlanivimab administration date |
covid19_treatment |
| atc_l01xc_2_date |
Bamlanivimab plus etesevimab administration date |
covid19_treatment |
| l04aa37_end |
Baricitinib end date |
covid19_treatment |
| l04aa37_start |
Baricitinib start date |
covid19_treatment |
| b02ab04_end |
Camostat end date |
covid19_treatment |
| b02ab04_start |
Camostat start date |
covid19_treatment |
| l04ac08_end |
Canakinumab end date |
covid19_treatment |
| l04ac08_start |
Canakinumab start date |
covid19_treatment |
| atc_l01xc_3_date |
Casirivimab plus imdevimab administration date |
covid19_treatment |
| sct_281789004_cause_agent |
Causative agent |
covid19_treatment |
| sct_281789004_cause_agent1 |
Causative agent - other specify |
covid19_treatment |
| p01ba01_end |
Chloroquine end date |
covid19_treatment |
| p01ba01_start |
Chloroquine start date |
covid19_treatment |
| b01ac23_end |
Cilostazol end date |
covid19_treatment |
| b01ac23_start |
Cilostazol start date |
covid19_treatment |
| sct_281789004_class |
Class of antibiotic therapy used |
covid19_treatment |
| sct_281789004_class_other |
Class of antibiotic therapy used - other specify |
covid19_treatment |
| b01ac04_end |
Clopidogrel end date |
covid19_treatment |
| b01ac04_start |
Clopidogrel start date |
covid19_treatment |
| l01cc_end |
Colchicine end date |
covid19_treatment |
| l01cc_start |
Colchicine start date |
covid19_treatment |
| conval_plasma_end |
Convalescent plasma end date |
covid19_treatment |
| conval_plasma_start |
Convalescent plasma start date |
covid19_treatment |
| atc_convalescent_plasma |
Convalescent plasma used |
covid19_treatment |
| sct_304275008 |
Corticosteroid usedMeans therapy used with the purpose of Covid-19 treatment |
covid19_treatment |
| l04ad01_end |
Cyclosporin A end date |
covid19_treatment |
| l04ad01_start |
Cyclosporin A start date |
covid19_treatment |
| j05ae10_end |
Darunavir end date |
covid19_treatment |
| j05ae10_start |
Darunavir start date |
covid19_treatment |
| sct_703503000_14 |
Data collector - Treatment |
covid19_treatment |
| sct_399651003_14 |
Date of collection - Treatment |
covid19_treatment |
| a01ac02_route |
Dexamethasone administration route
|
covid19_treatment |
| a01ac02_end |
Dexamethasone end date Include ONLY the time period before steroids descalation |
covid19_treatment |
| a01ac02_dose |
Dexamethasone highest mg/day used |
covid19_treatment |
| a01ac02_start |
Dexamethasone start date |
covid19_treatment |
| b01ac07_end |
Dipyridamole end date |
covid19_treatment |
| b01ac07_start |
Dipyridamole start date |
covid19_treatment |
| sct_182764009_end_date_2 |
Direct oral anticoagulants end date |
covid19_treatment |
| sct_182764009_start_date_3 |
Direct oral anticoagulants start date |
covid19_treatment |
| l04aa39_end |
Emapalumab end date |
covid19_treatment |
| l04aa39_start |
Emapalumab start date |
covid19_treatment |
| l04ab01_end |
Etanercept end date |
covid19_treatment |
| l04ab01_start |
Etanercept start date |
covid19_treatment |
| l01eg02_end |
Everolimus end date |
covid19_treatment |
| l01eg02_start |
Everolimus start date |
covid19_treatment |
| sct_233573008 |
Extracorporeal support (ECMO) used |
covid19_treatment |
| sct_371908008_end |
Face mask (simple mask, Venturi mask) end date |
covid19_treatment |
| sct_371908008_start |
Face mask (simple mask, Venturi mask) start date |
covid19_treatment |
| sct_371908008_26397000_e |
Face mask with reservoir end date |
covid19_treatment |
| sct_371908008_26397000_s |
Face mask with reservoir start date |
covid19_treatment |
| j05ax27_end |
Favipiravir end date |
covid19_treatment |
| j05ax27_start |
Favipiravir start date |
covid19_treatment |
| sct_182764009_end_date_4 |
Fondaparinux end date |
covid19_treatment |
| sct_182764009_start_date_5 |
Fondaparinux start date |
covid19_treatment |
| sct_870533002_end |
High-flow nasal cannula end date |
covid19_treatment |
| sct_870533002_start |
High-flow nasal cannula start date |
covid19_treatment |
| p01ba02_end |
Hydroxychloroquine end date |
covid19_treatment |
| p01ba02_start |
Hydroxychloroquine start date |
covid19_treatment |
| sct_372558009 |
Immunomodulator agent usedMeans therapy used with the purpose of Covid-19 treatment |
covid19_treatment |
| sct_405626009 |
Inhaled nitric oxide given |
covid19_treatment |
| sct_373213009_870406003 |
Inotropes / vasopressors used |
covid19_treatment |
| l03ab01_end |
Interferon alpha end date |
covid19_treatment |
| l03ab01_start |
Interferon alpha start date |
covid19_treatment |
| l03ab02_end |
Interferon beta end date |
covid19_treatment |
| l03ab02_start |
Interferon beta start date |
covid19_treatment |
| d11ax22_end |
Ivermectin end date |
covid19_treatment |
| d11ax22_start |
Ivermectin start date |
covid19_treatment |
| j05ar10_end |
Lopinavir/ritonavir end date |
covid19_treatment |
| j05ar10_start |
Lopinavir/ritonavir start date |
covid19_treatment |
| sct_182764009_end_date_5 |
Low molecular weight heparin end date |
covid19_treatment |
| sct_182764009_start_date_6 |
Low molecular weight heparin start date |
covid19_treatment |
| sct_40617009_end |
Mechanical ventilation end date |
covid19_treatment |
| sct_40617009_start |
Mechanical ventilation start date |
covid19_treatment |
| d07aa01_route |
Methylprednisolone administration route |
covid19_treatment |
| d07aa01_end |
Methylprednisolone end dateInclude ONLY the time period before steroids descalation |
covid19_treatment |
| d07aa01_dose |
Methylprednisolone highest mg/day used |
covid19_treatment |
| d07aa01_start |
Methylprednisolone start date |
covid19_treatment |
| atc_l01xc |
Monoclonal antibodies usedMeans therapy used with the purpose of Covid-19 treatment |
covid19_treatment |
| new_monocl_specify |
Monoclonal antibody other (specify) |
covid19_treatment |
| sct_371907003_end |
Nasal prongs end date |
covid19_treatment |
| sct_371907003_start |
Nasal prongs start date |
covid19_treatment |
| j05ah_start |
Neuraminidade inhibitors start date |
covid19_treatment |
| j05ah_end |
Neuraminidase inhibitors end date |
covid19_treatment |
| sct_428311008_end |
Non-invasive ventilation (CPAP/BIPAP) end date |
covid19_treatment |
| sct_428311008_start |
Non-invasive ventilation (CPAP/BIPAP) start date |
covid19_treatment |
| new_anticoag_specify |
Other anticoagulant used (specify) |
covid19_treatment |
| sct_788081006_other |
Other antiviral agent (specify) |
covid19_treatment |
| sct_304275008_other |
Other corticosteroids used (specify) |
covid19_treatment |
| therapy_other_specify |
Other drug (specify) |
covid19_treatment |
| therapy_other |
Other drugs usedMeans therapy used with the purpose of Covid-19 treatment |
covid19_treatment |
| sct_372558009_specify |
Other immunomodulator agent (specify) |
covid19_treatment |
| sct_771452004_specify |
Other platelet aggregation inhibitor (specify) |
covid19_treatment |
| sct_57485005_max |
Oxygen therapy maximum flow volume (L/min) |
covid19_treatment |
| sct_57485005 |
Oxygen therapy usedSelect all the respiratory support provided to the patient |
covid19_treatment |
| sct_771452004 |
Platelet aggregation inhibitor usedMeans therapy used with the purpose of Covid-19 treatment |
covid19_treatment |
| b01ac22_end |
Prasugrel end date |
covid19_treatment |
| b01ac22_start |
Prasugrel start date |
covid19_treatment |
| a07ea03_route |
Prednisone administration route |
covid19_treatment |
| a07ea03_end |
Prednisone end dateInclude ONLY the time period before steroids descalation |
covid19_treatment |
| a07ea03_dose |
Prednisone highest mg/day used |
covid19_treatment |
| a07ea03_start |
Prednisone start date |
covid19_treatment |
| sct_431182000 |
Prone position (decubitus ventral) applied |
covid19_treatment |
| sct_870391004 |
Prone ventilation performed |
covid19_treatment |
| sct_182764009_purpose_2 |
Purpose of [new_anticoag_specify] therapy Intermediate dose corresponds to a dose between normal prophylaxis and treatment dose |
covid19_treatment |
| sct_182764009_purpose_3 |
Purpose of direct oral anticoagulants therapy Intermediate dose corresponds to a dose between normal prophylaxis and treatment dose |
covid19_treatment |
| sct_182764009_purpose_5 |
Purpose of fondaparinux therapy Intermediate dose corresponds to a dose between normal prophylaxis and treatment dose |
covid19_treatment |
| sct_182764009_purpose_6 |
Purpose of low molecular weight heparin therapy Intermediate dose corresponds to a dose between normal prophylaxis and treatment dose |
covid19_treatment |
| sct_182764009_purpose |
Purpose of unfractioned heparin therapy Intermediate dose corresponds to a dose between normal prophylaxis and treatment dose |
covid19_treatment |
| sct_182764009_purpose_4 |
Purpose of vitamin K antagonist therapy Intermediate dose corresponds to a dose between normal prophylaxis and treatment dose |
covid19_treatment |
| j05ab16_end |
Remdesivir end date |
covid19_treatment |
| j05ab16_start |
Remdesivir start date |
covid19_treatment |
| sct_398887003_265764009 |
Renal replacement therapy (RRT) or dialysis used |
covid19_treatment |
| j05ap01_end |
Ribavirin end date |
covid19_treatment |
| j05ap01_start |
Ribavirin start date |
covid19_treatment |
| l01ej01_end |
Ruxolitinib end date |
covid19_treatment |
| l01ej01_start |
Ruxolitinib start date |
covid19_treatment |
| l04ac14_end |
Sarilumab end date |
covid19_treatment |
| l04ac14_start |
Sarilumab start date |
covid19_treatment |
| l04ac11_end |
Siltuximab end date |
covid19_treatment |
| l04ac11_start |
Siltuximab start date |
covid19_treatment |
| l04aa10_end |
Sirolimus end date |
covid19_treatment |
| l04aa10_start |
Sirolimus start date |
covid19_treatment |
| sct_315053001_end |
Statins end date |
covid19_treatment |
| sct_315053001_start |
Statins start date |
covid19_treatment |
| d11ah01_end |
Tacrolimus end date |
covid19_treatment |
| d11ah01_start |
Tacrolimus start date |
covid19_treatment |
| b01ac24_end |
Ticagrelor end date |
covid19_treatment |
| b01ac24_start |
Ticagrelor start date |
covid19_treatment |
| b01ac05_end |
Ticlopidine end date |
covid19_treatment |
| b01ac05_start |
Ticlopidine start date |
covid19_treatment |
| l04ac07_end |
Tocilizumab end date |
covid19_treatment |
| l04ac07_start |
Tocilizumab start date |
covid19_treatment |
| sct_697984004 |
Tracheostomy inserted |
covid19_treatment |
| b01ac18_end |
Triflusal end date |
covid19_treatment |
| b01ac18_start |
Triflusal start date |
covid19_treatment |
| sct_182764009_end_date |
Unfractioned heparin end date |
covid19_treatment |
| sct_182764009_start_date |
Unfractioned heparin start date |
covid19_treatment |
| sct_182764009_end_date_3 |
Vitamin K antagonist end date |
covid19_treatment |
| sct_182764009_start_date_4 |
Vitamin K antagonist start date |
covid19_treatment |
| sct_281789004_cause |
Was the bacterial infection clinically suspected or documented? |
covid19_treatment |
| sct_281789004_other |
Which bacterial infection was clinically suspected or documented - other (specify) |
covid19_treatment |
| sct_281789004_purpose |
Which bacterial infection was clinically suspected or documented? |
covid19_treatment |
| bdnf_analysis |
BDNF concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_1988_5 |
CRP concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ctack_analysis |
CTACK concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| sct_32813003_439771001 |
Cytokine analysis - date of sample collection |
cytokine_analysis_edta_plasma |
| sct_32813003_id |
Cytokine analysis ORCHESTRA sample ID |
cytokine_analysis_edta_plasma |
| sct_703503000_22 |
Data collector - Cytokine Analysis |
cytokine_analysis_edta_plasma |
| sct_399651003_22 |
Date of collection - Cytokine Analysis |
cytokine_analysis_edta_plasma |
| eotaxin_analysis |
Eotaxin concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_15061_5 |
EPO concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| fgf_basic_concentration |
FGF-2 basic concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_74756_8 |
Flt concentration (in pg/mL)LP182307-1 Soluble fms-like tyrosine kinase-1 Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein that disables proteins that cause blood vessel growth. Soluble Flt-1 (sFlt-1) is a splice variant of VEGF receptor 1 (Flt-1) which is produced by a variety of tissues.1 These proteins act as a receptor of vascular endothelial growth factor (VEGF), a potent angiogenic growth factor. Serum levels of sFlt-1 are altered in women with preeclampsia. |
cytokine_analysis_edta_plasma |
| fractalkine_analysis |
Fractalkine concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_54458_5 |
G-CSF concentration (in pg/mL)LP89646-1 Granulocyte colony stimulating factor Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. It is a glycoprotein, growth factor or cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood. It also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. G-CSF is also known as colony-stimulating factor 3 (CSF 3) |
cytokine_analysis_edta_plasma |
| gm_csf_analysis |
GM-CSF concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| sct_32813003 |
Has a sample for cytokine analysis been collected? |
cytokine_analysis_edta_plasma |
| ln_79394_3 |
HGF concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| icam_analysis |
ICAM-1 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ifn_beta_analysis |
IFN-beta concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_27415_9 |
IFN-gamma concentration (in pg/mL)LP18171-6 Interferon.gamma Interferon-gamma (IFN-γ) is a dimerized soluble cytokine that is the only member of the type II class of interferons.This interferon was originally called macrophage-activating factor, a term now used to describe a larger family of proteins to which IFN-γ belongs |
cytokine_analysis_edta_plasma |
| ln_26848_2 |
IL-10 concentration (in pg/mL)LP21163-8 Interleukin 10 Interleukin-10 (IL-10 or IL10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. In humans IL-10 is encoded by the IL10 gene.
This cytokine is produced primarily by monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II antigens, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. This cytokine can block NF-κB activity, and is involved in the regulation of the JAK-STAT signaling pathway. |
cytokine_analysis_edta_plasma |
| ln_41760_0_p40 |
IL-12/IL23p40 concentration (in pg/mL)LP18174-0 Interleukin 12 Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells[1], macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is linked with autoimmunity. |
cytokine_analysis_edta_plasma |
| ln_41760_0 |
IL-12p70 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_33822_8 |
IL-13 concentration (in pg/mL)LP31544-7 Interleukin 13 Interleukin 13 (IL-13) is a cytokine secreted by many cell types, but especially T helper type 2 (Th2) cells, that is an important mediator of allergic inflammation and disease. |
cytokine_analysis_edta_plasma |
| il_15_analysis |
IL-15 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| il_16_analysis |
IL-16 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_82334_4 |
IL-17A concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| il_17f_concentration |
IL-17F concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_33823_6 |
IL-18 concentration (in pg/mL)LP31545-4 Interleukin 18 Interleukin-18 also known as IL18 is a protein which in humans is encoded by the IL18 gene. The protein encoded by this gene is a proinflammatory cytokine. IL-18 is able to induce severe inflammatory reactions, which suggests its role in certain inflammatory disorders. |
cytokine_analysis_edta_plasma |
| ln_13629_1 |
IL-1beta concentration (in pg/mL)LP18509-7 Interleukin 1 beta Interleukin 1, beta, also known as IL1B, is a cytokine protein which in humans is encoded by the IL1B gene. IL-1β precursor is cleaved by caspase 1 (interleukin 1 beta convertase). Cytosolic thiol protease cleaves the product to form mature IL-1β.
A number of studies associate the gene with susceptibility to schizophrenia |
cytokine_analysis_edta_plasma |
| ln_34407_7 |
IL-1RA concentration (in pg/mL)LP16469-6 Interleukin 1 Interleukin-1 (IL-1) refers to a group of three polypeptides (interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1ß) and interleukin-1 receptor antagonist (IL-1Ra)), that play a central role in the regulation of immune and inflammatory responses. |
cytokine_analysis_edta_plasma |
| ln_33939_0 |
IL-2 concentration (in pg/mL)LP16470-4 Interleukin 2 Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. |
cytokine_analysis_edta_plasma |
| il_21_concentration |
IL-21 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| il_22_concentration |
IL-22 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| il_23_concentration |
IL-23 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_43171_8 |
IL-2R concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| il_2ra_analysis |
IL-2Ra concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_70081_5 |
IL-3 concentration (in pg/mL)LP16471-2 Interleukin 3 Interleukin 3, also known as IL-3, is a protein that in humans is encoded by the IL3 gene. |
cytokine_analysis_edta_plasma |
| il_33_concentration |
IL-33 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_27161_9 |
IL-4 concentration (in pg/mL)LP16472-0 Interleukin 4 Interleukin-4, abbreviated IL-4, is a cytokine that induces differentiation of naive helper T cells (Th0 cells) to Th2 cells. Upon activation by IL-4, Th2 cells subsequently produce additional IL-4. The cell that initially produces IL-4, thus inducing Th0 differentiation, has not been identified, but recent studies suggest that basophils may be the effector cell.
It has many biological roles, including the stimulation of activated B-cell and T-cell proliferation, and the differentiation of CD4+ T-cells into Th2 cells. It is a key regulator in humoral and adaptive immunity. IL-4 induces B-cell class switching to IgE, and up-regulates MHC class II production. Overproduction of IL-4 is associated with allergies. |
cytokine_analysis_edta_plasma |
| ln_33938_2 |
IL-5 concentration (in pg/mL)LP16473-8 Interleukin 5 Interleukin 5 or IL-5 is an interleukin produced by T helper-2 cells and mast cells. Its functions are to stimulate B cell growth and increase immunoglobulin secretion. It is also a key mediator in eosinophil activation. IL-5 is a 115 amino acid (in man, 133 in the mouse) long TH2 cytokine which is part of the hematopoietic family.Interleukin-5 is also expressed by eosinophils and has been observed in the mast cells of asthmatic airways by immunohistochemistry. IL-5 expression is regulated by several transcription factors including GATA3. |
cytokine_analysis_edta_plasma |
| ln_26881_3 |
IL-6 concentration (in pg/mL)LP16474-6 Interleukin 6 Interleukin-6 (IL-6) is a protein that in humans is encoded by the IL6 gene.
IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. In terms of host response to a foreign pathogen, IL-6 has been shown, in mice, to be required for resistance against the bacterium, Streptococcus pneumoniae. IL-6 is also a "myokine," a cytokine produced from muscle, and is elevated in response to muscle contraction. It is significantly elevated with exercise, and precedes the appearance of other cytokines in the circulation. During exercise, it is thought to act in a hormone-like manner to mobilize extracellular substrates and/or augment substrate delivery. Additionally, osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine. IL-6's role as an anti-inflammatory cytokine is mediated through its inhibitory effects on TNF-alpha and IL-1, and activation of IL-1ra and IL-10. |
cytokine_analysis_edta_plasma |
| ln_70088_0 |
IL-7 concentration (in pg/mL)LP16475-3 Interleukin 7 Interleukin 7 (IL7) is a protein[1] that is encoded by the IL7 gene in humans.
IL-7 a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, neurons and endothelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells (as opposed to myeloid progenitor cells where differentiation is stimulated by IL-3). It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis.
IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. This cytokine is found to be a cofactor for V(D)J rearrangement of the T cell receptor beta (TCRB) during early T cell development. This cytokine can be produced locally by intestinal epithelial and epithelial goblet cells, and may serve as a regulatory factor for intestinal mucosal lymphocytes. Knockout studies in mice suggested that this cytokine plays an essential role in lymphoid cell survival.
IL-7 receptor knockout mice exhibit thymic atrophy, arrest of T-cell development at the double positive stage, and severe lymphopenia. Administration of IL-7 to mice results in an increase in thymic migrants, increases in B and T cells, and increased recovery of T cells after cyclophosphamide administration or after bone marrow transplantation.
Il-7 promotes hematological malignacies (acute lymphoblastic leukemia, T cell lymphoma). |
cytokine_analysis_edta_plasma |
| ln_33211_4 |
IL-8 concentration (in pg/mL)LP30829-3 Interleukin 8 Interleukin-8 (IL-8) is a chemokine produced by macrophages and other cell types such as epithelial cells. It is also synthesized by endothelial cells, which store IL-8 in their storage vesicles, the Weibel-Palade bodies. In humans, the interleukin-8 protein is encoded by the IL8 gene.
Interleukin-8 is often associated with inflammation. As an example, it has been cited as a proinflammatory mediator in gingivitis and psoriasis. The fact that Interleukin-8 secretion is increased by oxidant stress and conversely, Interleukin-8, by causing recruitment of inflammatory cells induces a further increase in oxidant stress mediators, makes it a key parameter in localized inflammation.
If a pregnant mother has high levels of interleukin-8, there is an increased risk of schizophrenia in her offspring. High levels of Interleukin 8 have been shown to reduce the likelihood of positive responses to antipsychotic medication in schizophrenia. |
cytokine_analysis_edta_plasma |
| il_9_analysis |
IL-9 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ip_10_analysis |
IP-10 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| kc_gro_analysis |
KC-GRO concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| mcp_1_analysis |
MCP-1 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| mcp_2_analysis |
MCP-2 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| mcp_3_analysis |
MCP-3 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| m_csf_analysis |
M-CSF concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| mig_analysis |
MIG concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| mip_1alpha_analysis |
MIP-1alpha concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| mip_1beta_analysis |
MIP-1beta concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| mip_3alpha_analysis |
MIP-3alpha concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| pdgfbb_pdgf_b_analysis |
PDGFbb/PDGF-B concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_74755_0 |
PlGF concentration (in pg/mL)LP182306-3 Placental growth factor Placental growth factor is a protein that in humans is encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor) sub-family - a key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. Serum levels of PGF and sFlt-1 (soluble fms-like tyrosine kinase-1, also known as soluble VEGF receptor-1) are altered in women with preeclampsia. |
cytokine_analysis_edta_plasma |
| rantes_analysis |
RANTES concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_48498_0 |
SAA concentration (in pg/mL)LP63040-7 Amyloid A Serum amyloid A (SAA) proteins are a family of apolipoproteins associated with high-density lipoprotein (HDL). Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs or A-SAAs). A-SAAs are secreted during the acute phase of inflammation and are implicated in several chronic inflammatory diseases, such as amyloidosis, atherosclerosis, and rheumatoid arthritis. PMID: 15944321 Amyloid A (AA) protein quantification in tissue specimens is a sensitive and specific method for detection of clinical AA amyloidosis. PMID: 17577686 |
cytokine_analysis_edta_plasma |
| ln_49853_5 |
TGF-beta (active) concentration (in pg/mL)LP64930-8 Transforming growth factor beta 1 Transforming growth factor beta 1 or TGF-β1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. In humans, TGF-β1 is encoded by the TGFB1 gene.
TGF-β1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGF-β1 |
cytokine_analysis_edta_plasma |
| tgf_beta_total |
TGF-beta (total) concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| tie_2_analysis |
Tie-2 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_3074_2 |
TNF-alpha concentration (in pg/mL)LP18480-1 Tumor necrosis factor.alpha Tumor necrosis factor (TNF, cachexin or cachectin and formally known as tumor necrosis factor-alpha) is a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction.
The primary role of TNF is in the regulation of immune cells. TNF is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNF production has been implicated in a variety of human diseases, as well as cancer. Recombinant TNF is used as an immunostimulant under the INN tasonermin. |
cytokine_analysis_edta_plasma |
| tslp_concentration |
TSLP concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| vap_1_analysis |
VAP-1 concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_75627_0 |
VCAM concentration (in pg/mL)LP185746-7 Vascular adhesion protein 1 Vascular cell adhesion molecule 1 (VCAM-1) is a protein that in humans is encoded by the VCAM1 gene. The VCAM-1 protein mediates the adhesion of lymphocytes, monocytes, eosinophils, and basophils to vascular endothelium. It also functions in leukocyte-endothelial cell signal transduction, and it may play a role in the development of atherosclerosis and rheumatoid arthritis. |
cytokine_analysis_edta_plasma |
| ln_34694_0 |
VEGF-A concentration (in pg/mL)LP32721-0 Vascular endothelial growth factor Vascular endothelial growth factor (VEGF) is a sub-family of growth factors, specifically the platelet-derived growth factor family of cystine-knot growth factors. The most important member is VEGF-A. Other members are Placenta growth factor (PGF), VEGF-B, VEGF-C and VEGF-D. The latter ones were discovered later than VEGF-A, and, before their discovery, VEGF-A was called just VEGF.
VEGF growth factors are important signaling proteins involved in both vasculogenesis and angiogenesis. When these growth factors are overexpressed, they can contribute to conditions such as cancer, bronchial asthma and diabetes mellitus. Overexpression of VEGFs can also cause vascular disease in the retina of the eye and other parts of the body. Drugs such as bevacizumab can inhibit VEGFs and control or slow those diseases. |
cytokine_analysis_edta_plasma |
| vegf_c_analysis |
VEGF-C concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| ln_82911_9 |
VEGF-D concentration (in pg/mL) |
cytokine_analysis_edta_plasma |
| sct_32813003_ship |
Was the cytokine analysis performed locally or the samples shipped to WP6 laboratory? |
cytokine_analysis_edta_plasma |
| sct_32813003_272392009 |
Which assay was used? |
cytokine_analysis_edta_plasma |
| sct_184099003 |
Date of birth |
demographics |
| sct_263495000 |
Biological sex |
demographics |
| sct_372148003 |
Ethnic group |
demographics |
| sct_372148003_1 |
Ethnic group |
demographics |
| sct_399651003_2 |
Date of collection - Demographics |
demographics |
| sct_703503000_2 |
Data collector - Demographics |
demographics |
| bioinfo_processing_ref |
Bioinformatic processing details |
epigenetics_methylation_edta_whole_blood |
| sct_703503000_24 |
Data collector - Epigenetics methylation |
epigenetics_methylation_edta_whole_blood |
| sct_399651003_24 |
Date of collection - Epigenetics methylation |
epigenetics_methylation_edta_whole_blood |
| ncit_c164023 |
Date of measurementThe date for the first round of genomic sequencing of a subject's DNA. |
epigenetics_methylation_edta_whole_blood |
| ncit_c63328_date |
Epigenetics methylation analysis - date of sample collectionThe analysis of the methylated deoxyribonucleotides present in the genome in a biological sample. |
epigenetics_methylation_edta_whole_blood |
| ncit_c63328_id |
Epigenetics methylation analysis ORCHESTRA sample IDThe analysis of the methylated deoxyribonucleotides present in the genome in a biological sample. |
epigenetics_methylation_edta_whole_blood |
| ln_62374_4 |
Genome assembly version used as reference in imputation? |
epigenetics_methylation_edta_whole_blood |
| ncit_c63328_avail |
Has a sample for epigenetics methylation analysis been collected?The analysis of the methylated deoxyribonucleotides present in the genome in a biological sample. |
epigenetics_methylation_edta_whole_blood |
| ncit_c180318 |
Illumina Sentrix IDAn identifirer from an illumina sentrix array containing the sequencing plate number and positional information about the samples being processed. |
epigenetics_methylation_edta_whole_blood |
| ncit_c180319 |
Illumina Sentrix PositionThe row and column position for a well on a nucleotide sequencing plate where a sample resides. |
epigenetics_methylation_edta_whole_blood |
| sct_363779003 |
Is genotyping data on the same sample available? |
epigenetics_methylation_edta_whole_blood |
| ln_62374_4_oth |
Other genome assembly version used as reference in imputation? |
epigenetics_methylation_edta_whole_blood |
| seq_performer_other_1 |
Other Partner who performed the sequencing
|
epigenetics_methylation_edta_whole_blood |
| ncit_c45447_imput_oth |
Other value set for imputation methods - specify::The determination of the DNA sequence of an individual. |
epigenetics_methylation_edta_whole_blood |
| ncit_c15311_person |
Quality control (QC) performed bySet of measurements and inspections taken to verify that performance of equipment and procedures remains within specified limits. |
epigenetics_methylation_edta_whole_blood |
| ncit_c15311_pass |
Quality control passed?Set of measurements and inspections taken to verify that performance of equipment and procedures remains within specified limits. |
epigenetics_methylation_edta_whole_blood |
| ncit_c146817 |
Sequencing machine usedA proprietary next-generation DNA sequencing system from Solexa that uses reversible terminator nucleotides. The genomic DNA to be sequenced is fragmented and ligated to adapter molecules on both ends to construct an Illumina-specific adapter library. PCR amplification of the DNA fragments is then performed using the adapter sequence as primer. Sequencing is carried out by repeated cycles of adding reversible fluorescent-labelled nucleotide and incorporation of the nucleotides to the complementary strand. The fluorescence of the incorporated nucleotides is detected. |
epigenetics_methylation_edta_whole_blood |
| ncit_c180320 |
Sequencing plate numberA number that identifies a sequencing plate. |
epigenetics_methylation_edta_whole_blood |
| ncit_c172274 |
Sequencing platform (PL) used The name of the technology platform used to perform nucleic acid sequencing. |
epigenetics_methylation_edta_whole_blood |
| ncit_c165222_other |
Specify other methylation array usedThe use of a high-throughput microarray where all of the known CpG islands either in a single specimen or all of the known promoter sequences of a specimen or a population group are coupled to beads or microwells to determine which are methylated. |
epigenetics_methylation_edta_whole_blood |
| ncit_c146817_other |
Specify other sequencing machine usedA proprietary next-generation DNA sequencing system from Solexa that uses reversible terminator nucleotides. The genomic DNA to be sequenced is fragmented and ligated to adapter molecules on both ends to construct an Illumina-specific adapter library. PCR amplification of the DNA fragments is then performed using the adapter sequence as primer. Sequencing is carried out by repeated cycles of adding reversible fluorescent-labelled nucleotide and incorporation of the nucleotides to the complementary strand. The fluorescence of the incorporated nucleotides is detected. |
epigenetics_methylation_edta_whole_blood |
| ncit_c172274_other |
Specify other sequencing platform usedThe name of the technology platform used to perform nucleic acid sequencing. |
epigenetics_methylation_edta_whole_blood |
| ncit_c63328_other |
Specify other methylation analysis technology usedThe analysis of the methylated deoxyribonucleotides present in the genome in a biological sample. |
epigenetics_methylation_edta_whole_blood |
| ncit_c63328 |
Technology used for methylation analysisThe analysis of the methylated deoxyribonucleotides present in the genome in a biological sample. |
epigenetics_methylation_edta_whole_blood |
| ln_81304_8 |
Variant analysis method used? |
epigenetics_methylation_edta_whole_blood |
| ncit_c63328_ship |
Was the epigenetics methylation analysis performed locally or the samples shipped to WP6 laboratory?The analysis of the methylated deoxyribonucleotides present in the genome in a biological sample. |
epigenetics_methylation_edta_whole_blood |
| ncit_c165222 |
What methylation array was used?The use of a high-throughput microarray where all of the known CpG islands either in a single specimen or all of the known promoter sequences of a specimen or a population group are coupled to beads or microwells to determine which are methylated. |
epigenetics_methylation_edta_whole_blood |
| ncit_c45447_imput |
Which imputation method was used?::The determination of the DNA sequence of an individual. |
epigenetics_methylation_edta_whole_blood |
| sct_26929004 |
Alzheimer's disease since the last visit No changes means stable disease |
new_medical_events |
| sct_363346000_type1 |
Specification of the active tumor/ cancer disease |
fragile_population |
| sct_370388006 |
Immunosuppressive conditions |
fragile_population |
| sct_414029004_specify |
Other immunosuppressive conditions - specify |
fragile_population |
| sct_414029004_type |
Other immunosuppressive conditions |
fragile_population |
| sct_86044005 |
Amyotrophic lateral sclerosis since the last visit No changes means stable disease |
new_medical_events |
| sct_703503000_10 |
Data collector - Biometric Parameters |
biometric_parameters |
| sct_399651003_10 |
Date of collection - Biometric Parameters |
biometric_parameters |
| sct_365981007 |
Has the patient ever smoked cigarettes? |
biometric_parameters |
| sct_161663000_type |
Transplant description |
fragile_population |
| sct_70719008_collector |
Data collector - IFN-gamma analysis |
ifngamma_analysis_serumplasma |
| sct_70719008_date |
Date of collection - IFN-gamma analysis |
ifngamma_analysis_serumplasma |
| ln_95971_8 |
Has a sample for IFN-gamma analysis been collected?LP420517-7 SARS coronavirus 2 stimulated gamma interferon A durable T cell immune response to SARS-CoV-2 has been demonstrated that is a more sensitive
|
ifngamma_analysis_serumplasma |
| ln_95971_8_date |
IFN-gamma analysis - date of sample collection |
ifngamma_analysis_serumplasma |
| ln_95971_8_id |
IFN-gamma analysis ORCHESTRA sample ID |
ifngamma_analysis_serumplasma |
| ln_95973_4 |
IFN-gamma release (in pg/mL) |
ifngamma_analysis_serumplasma |
| ln_95971_8_ship |
Was the IFN-gamma test performed locally or the sample shipped to WP6 laboratory? |
ifngamma_analysis_serumplasma |
| record_id |
REDCap ID |
inclusion_criteria |
| ncit_c45262 |
Data collector - intestinal microbiomeIndicates the person, group, or institution who performed the collection act. |
intestinal_microbiome_stool_or_rectal_swab |
| sct_399445004 |
Date of collection - intestinal microbiome |
intestinal_microbiome_stool_or_rectal_swab |
| sct_197480006 |
Anxiety disorder since the last visit No changes means stable disease |
new_medical_events |
| sct_195967001 |
Asthma since the last visitNo changes means stable disease |
new_medical_events |
| sct_414029004_specify_2 |
Auto-inflammatory disease new diagnosis (specify) |
new_medical_events |
| sct_414029004_type_2 |
Auto-inflammatory disease since the last visit
No changes means stable disease |
new_medical_events |
| ncit_c93019 |
Has a sample for Intestinal microbiome been collected?The collection of microorganisms existing in the intestines of an organism. |
intestinal_microbiome_stool_or_rectal_swab |
| ncit_c93019_date |
Intestinal microbiome - date of sample collectionThe collection of microorganisms existing in the intestines of an organism. |
intestinal_microbiome_stool_or_rectal_swab |
| bioinfo_processing_ref_2 |
Bioinformatic processing details |
human_genomics_edta_whole_blood |
| sct_169741004 |
Breastfeeding since the last visit |
new_medical_events |
| sct_698247007 |
Cardiac arrhythmia since the last visitNo changes means stable disease |
new_medical_events |
| child_pugh_final_score_fup |
Child Pugh final score |
new_medical_events |
| child_pugh_score_albumin1 |
Child Pugh score - albumin |
new_medical_events |
| child_pugh_score_ascites1 |
Child Pugh score - Ascites |
new_medical_events |
| child_pugh_score_enceph1 |
Child Pugh score - Encephalopathy |
new_medical_events |
| child_pugh_score_inr1 |
Child Pugh score - INR |
new_medical_events |
| child_pugh_score_bilirub1 |
Child Pugh score - total bilirubin |
new_medical_events |
| sct_709044004_1 |
Chronic kidney disease since the last visitDefinition of chronic kidney diseases: kidney damage for > 3 months. Possible causes: primary glomerular disease (focal segmental glomerulosclerosis, IgA nephropathy) secondary glomerular disease (diabetes with renal complications, systemic lupus erythematosus), tubulointerstitial diseases (sarcoidoisis, drug-induced, urate, environmental toxins, myeloma), obstructive nephropathy, vascular diseases (atherosclerosis, hypertension, ischemia, cholesterol emboli, systemic vasculitis, thrombotic microangiopathy, systemic sclerosis), xystic and congenital diseases (polycystic kidney disease, Alport's syndrome, Fabry's disease)</p> <p><em><span style="font-size: 10px;"> No changes means stable disease |
new_medical_events |
| sct_328383001_specify1 |
Chronic liver disease since the last visit - specify |
new_medical_events |
| ln_76435_7 |
ORCHESTRA unique identifier: |
inclusion_criteria |
| sct_328383001_1 |
Chronic liver disease since the last visitDefinition of chronic liver diseases: alcohol induced liver disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), hereditary hemochromatosis, Wilsons disease
No changes means stable disease |
new_medical_events |
| sarscov2_test_date |
Date of SARS-CoV-2 confirmatory test |
inclusion_criteria |
| sct_118522005_dag |
DAG number |
inclusion_criteria |
| sct_309370004 |
Informed consent signed |
inclusion_criteria |
| sct_399651003_1 |
Date of collection - Inclusion |
inclusion_criteria |
| sct_55149002 |
Date of enrollment (date of informed consent signature) |
inclusion_criteria |
| sct_703503000_1 |
Data collector - Inclusion |
inclusion_criteria |
| sct_13645005 |
Chronic obstructive pulmonary disease since the last visitNo changes means stable disease |
new_medical_events |
| sct_19943007 |
Cirrhosis since the last visit No changes means stable disease |
new_medical_events |
| sct_42343007 |
Congestive heart failure since the last visitNo changes means stable disease |
new_medical_events |
| sct_53741008 |
Coronary artery disease since the last visitNo changes means stable disease |
new_medical_events |
| sct_719218000 |
Cryptogenic organizing pneumonia since the last visit No changes means stable disease |
new_medical_events |
| ncit_c93019_id |
Intestinal microbiome ORCHESTRA sample IDThe collection of microorganisms existing in the intestines of an organism. |
intestinal_microbiome_stool_or_rectal_swab |
| sct_703503000_genomics |
Data collector - human genomics |
human_genomics_edta_whole_blood |
| sct_225302006 |
Insulin therapy |
medical_history |
| sct_404640003 |
Dizziness/light headedness |
Long COVID |
| sct_413839001 |
Does the patient suffer from a chronic respiratory disease? |
medical_history |
| sct_413839001_specify |
Chronic respiratory disease |
medical_history |
| sct_49601007 |
Does the patient suffer from cardiovascular disease? |
medical_history |
| sct_49601007_type |
Which cardiovascular disease does the patient suffer from? |
medical_history |
| sct_56717001 |
Tuberculosis (TB) co-infection |
medical_history |
| sct_74627003 |
Diabetes complications |
medical_history |
| ln_94309_2 |
SARS-CoV-2 (COVID-19) RNA [Presence] in specimen by NAAT with probe detectionLP417540-4 SARS coronavirus 2 The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV had been reported internationally due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. PMID: 31953166 Reported illnesses range from minor or no respiratory symptoms to severe acute respiratory illness and death.
|
microbiological_tests |
| ln_94746_5 |
SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Respiratory specimen by NAAT with probe detectionLP417540-4 SARS coronavirus 2 The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV had been reported internationally due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. PMID: 31953166 Reported illnesses range from minor or no respiratory symptoms to severe acute respiratory illness and death.
|
microbiological_tests |
| sct_123038009_sarscov2 |
Other specimen where the SARS-CoV-2 test was performed - specify |
microbiological_tests |
| sct_371439000 |
Where was the SARS-CoV-2 test performed? |
microbiological_tests |
| sct_399651003_18 |
Date of collection - Microbiological Tests |
microbiological_tests |
| sct_703503000_18 |
Data collector - Microbiological Tests |
microbiological_tests |
| sct_871560001 |
SARS-CoV-2 PCR available?
Before the anti-SARS-CoV-2 vaccination, collect the data from the latest SARS-CoV-2 test before vaccination, if available.
During the Covid-19 episode collect the data from the first SARS-CoV-2 test available. During the follow-up visits reassess only if outside the normal ranges at the previous assessment or if clinically indicated. |
microbiological_tests |
| sct_871560001_date |
SARS-CoV-2 PCR date |
microbiological_tests |
| ln_75325_1_oth |
Others |
Long COVID |
| sct_703503000_7 |
Data collector - New Medical Events |
new_medical_events |
| sct_328383001 |
Does the patient suffer from chronic liver disease (other than cancer)? Definition of chronic liver diseases: Alcohol induced liver disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Autoimmune Hepatitis (AIH), Primary Biliary Cirrhosis (PBC), Hereditary Hemochromatosis, Wilsons' Disease |
medical_history |
| brs_q1 |
I tend to bounce back quickly after hard times |
psychological_scale_questionnaires |
| brs_q2 |
I have a hard time making it through stressful events |
psychological_scale_questionnaires |
| sct_399651003_genomics |
Date of collection - human genomics |
human_genomics_edta_whole_blood |
| brs_q3 |
It does not take me long to recover from a stressful event |
psychological_scale_questionnaires |
| brs_q4 |
It is hard for me to snap back when something bad happens |
psychological_scale_questionnaires |
| sct_399651003_7 |
Date of collection - New Medical Events |
new_medical_events |
| brs_q5 |
I usually come through difficult times with little trouble |
psychological_scale_questionnaires |
| brs_q6 |
I tend to take a long time to get over set-backs in my life |
psychological_scale_questionnaires |
| ncit_c164023_1 |
Date of sequencingThe date for the first round of genomic sequencing of a subject's DNA. |
human_genomics_edta_whole_blood |
| sct_128053003 |
Deep vein thrombosis since the last visit No changes means stable disease |
new_medical_events |
| sct_52448006 |
Dementia other than Alzheimer since the last visit No changes means stable disease |
new_medical_events |
| sct_73211009 |
Diabetes since the last visitNo changes means stable disease |
new_medical_events |
| ces_d_scale_1 |
I was bothered by things that usually don't bother me |
psychological_scale_questionnaires |
| sct_365981007_1 |
Did the patient start smoking after the last visit |
new_medical_events |
| sct_67406007 |
Disseminated intravascular coagulation since the last visit No changes means stable disease |
new_medical_events |
| ces_d_scale_10 |
I felt fearful |
psychological_scale_questionnaires |
| ces_d_scale_11 |
My sleep was restless |
psychological_scale_questionnaires |
| ces_d_scale_12 |
I was happy |
psychological_scale_questionnaires |
| ces_d_scale_13 |
I talked less than usual |
psychological_scale_questionnaires |
| ces_d_scale_14 |
I felt lonely |
psychological_scale_questionnaires |
| ces_d_scale_15 |
People were unfriendly |
psychological_scale_questionnaires |
| ces_d_scale_16 |
I enjoyed life |
psychological_scale_questionnaires |
| ces_d_scale_17 |
I had crying spells |
psychological_scale_questionnaires |
| sct_84757009 |
Epilepsy since the last visit No changes means stable disease |
new_medical_events |
| ces_d_scale_18 |
I felt sad |
psychological_scale_questionnaires |
| ces_d_scale_19 |
I felt that people dislike me |
psychological_scale_questionnaires |
| sct_74474003 |
Gastrointestinal hemorrhage since the last visit No changes means stable disease |
new_medical_events |
| ln_62374_4_v2 |
Genome assembly version used as reference in imputation? |
human_genomics_edta_whole_blood |
| ncit_c164388 |
Genome reference sequenceA published genetic sequence that is used as a reference sequence against which other sequences are compared. |
human_genomics_edta_whole_blood |
| ces_d_scale_2 |
I did not feel like eating; my appetite was poor |
psychological_scale_questionnaires |
| ln_86206_0_86205_2 |
Has a sample for human genomics analysis been collected? |
human_genomics_edta_whole_blood |
| ces_d_scale_20 |
I could not get "going" |
psychological_scale_questionnaires |
| ces_d_scale_3 |
I felt that I could not shake off the blues even with help from my family or friends |
psychological_scale_questionnaires |
| ces_d_scale_4 |
I felt that I was just as good as other people |
psychological_scale_questionnaires |
| ces_d_scale_5 |
I had trouble keeping my mind on what I was doing |
psychological_scale_questionnaires |
| ces_d_scale_6 |
I felt depressed |
psychological_scale_questionnaires |
| ces_d_scale_7 |
I felt that everything I did was an effort |
psychological_scale_questionnaires |
| ces_d_scale_8 |
I felt hopeful about the future |
psychological_scale_questionnaires |
| ces_d_scale_9 |
I thought my life had been a failure |
psychological_scale_questionnaires |
| ln_86206_0_86205_2_date |
Human genomics - date of sample collection |
human_genomics_edta_whole_blood |
| ln_86206_0_86205_2_id |
Human genomics ORCHESTRA sample ID |
human_genomics_edta_whole_blood |
| sct_38341003 |
Hypertension since the last visitNo changes means stable disease |
new_medical_events |
| ln_66822_8 |
In the last month, how often have you felt that you were unable to control the important things in your life? |
psychological_scale_questionnaires |
| ln_66824_4 |
In the last month, how often have you felt confident about your ability to handle your personal problems? |
psychological_scale_questionnaires |
| ln_66825_1 |
In the last month, how often have you felt that things were going your way? |
psychological_scale_questionnaires |
| ln_66830_1 |
In the last month, how often have you felt difficulties were piling up so high that you could not overcome them? |
psychological_scale_questionnaires |
| ln_66855_8 |
How often do you feel that you lack companionship? |
psychological_scale_questionnaires |
| ln_66864_0 |
How often do you feel left out? |
psychological_scale_questionnaires |
| ln_66867_3 |
How often do you feel isolated from others? |
psychological_scale_questionnaires |
| ln_68509_9 |
Not being able to stop or control worrying |
psychological_scale_questionnaires |
| ln_69689_8 |
Becoming easily annoyed or irritable |
psychological_scale_questionnaires |
| ln_69725_0 |
Feeling nervous, anxious, or on edge |
psychological_scale_questionnaires |
| ln_69733_4 |
Worrying too much about different things |
psychological_scale_questionnaires |
| ln_69734_2 |
Trouble relaxing |
psychological_scale_questionnaires |
| ln_69735_9 |
Being so restless that it is hard to sit still |
psychological_scale_questionnaires |
| ln_69736_7 |
Feeling afraid as if something awful might happen |
psychological_scale_questionnaires |
| ln_97500_3 |
During the last two weeks were you obliged to follow the 'vaccinated-tested-recovered' rule to: |
psychological_scale_questionnaires |
| ln_97500_3_oth |
Please specify place/event: |
psychological_scale_questionnaires |
| ln_98170_4_closed |
During the last two weeks were you obliged to wear masks in closed public areas (e.g. theaters, restaurants, cinema,...)? |
psychological_scale_questionnaires |
| lockdown |
During the last two weeks have you been in a lockdown? |
psychological_scale_questionnaires |
| min_distance |
During the last two weeks did you have to keep a minimum distance of 1.5 or 2 metres when contacting people outside your household? |
psychological_scale_questionnaires |
| school_closure |
During the last two weeks have the schools been closed? |
psychological_scale_questionnaires |
| sct_224407007 |
During the last two weeks did you need to do home office (either completely or only on several days/week)? |
psychological_scale_questionnaires |
| sct_1119350007_5th |
Did the patient receive a mRNA vaccine as fifth dose? |
sarscov2_vaccination |
| sct_68311008_assay |
Anti-IFN antibodies test - assay used |
serology_tests_serumplasma |
| sct_68311008_ql |
Anti-IFN antibodies test (qualitative) |
serology_tests_serumplasma |
| sct_68311008_qn |
Anti-IFN antibodies test (quantitative) |
serology_tests_serumplasma |
| sct_68311008 |
Anti-IFN antibodies test available? |
serology_tests_serumplasma |
| sct_68311008_date |
Anti-IFN antibodies test date |
serology_tests_serumplasma |
| ln_94762_2 |
Anti-SARS-CoV-2 (qualitative)LP417540-4 SARS coronavirus 2 The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV had been reported internationally due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. PMID: 31953166 Reported illnesses range from minor or no respiratory symptoms to severe acute respiratory illness and death.
|
serology_tests_serumplasma |
| ln_94762_2_2 |
Anti-SARS-CoV-2 (qualitative) |
serology_tests_serumplasma |
| ncit_c180312_2 |
Insert sizeThe number of nucleotides inserted into a sequencing vector. |
human_genomics_edta_whole_blood |
| ln_94762_2_3 |
Anti-SARS-CoV-2 (qualitative) |
serology_tests_serumplasma |
| ln_94769_7 |
Anti-SARS-CoV-2 (quantitative) LP417540-4 SARS coronavirus 2 The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV had been reported internationally due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. PMID: 31953166 Reported illnesses range from minor or no respiratory symptoms to severe acute respiratory illness and death.
|
serology_tests_serumplasma |
| ln_94769_7_2 |
Anti-SARS-CoV-2 (quantitative) |
serology_tests_serumplasma |
| ln_94769_7_3 |
Anti-SARS-CoV-2 (quantitative) |
serology_tests_serumplasma |
| sct_363779003_v2 |
Is genotyping data on the same sample available? |
human_genomics_edta_whole_blood |
| ln_94769_7_v2 |
Anti-SARS-CoV-2 quantitative unit |
serology_tests_serumplasma |
| ln_94769_7_v3 |
Anti-SARS-CoV-2 quantitative unit |
serology_tests_serumplasma |
| ln_94769_7_v4 |
Anti-SARS-CoV-2 quantitative unit |
serology_tests_serumplasma |
| ncit_c180317 |
Kit used for Whole Exome Sequencing (WES). None needed if WGS was performed.A packaged system consisting of the materials necessary to perform nucleotide sequencing. |
human_genomics_edta_whole_blood |
| ncit_c175893 |
Library ID (LB)A unique identifier assigned to a nucleotide sequencing library. |
human_genomics_edta_whole_blood |
| sct_7180009_45170000 |
Meningitis / encephalitis since the last visit No changes means stable disease |
new_medical_events |
| sct_46206005 |
Mood disorder since the last visit No changes means stable disease |
new_medical_events |
| sct_24700007 |
Multiple sclerosis since the last visit No changes means stable disease |
new_medical_events |
| sct_73297009 |
Muscular dystrophy since the last visit No changes means stable disease |
new_medical_events |
| sct_703503000_25 |
Data collector - Serology Tests |
serology_tests_serumplasma |
| sct_91637004 |
Myasthenia gravis since the last visit No changes means stable disease |
new_medical_events |
| sct_50920009 |
Myocarditis since the last visitNo changes means stable disease |
new_medical_events |
| sct_363346000 |
New diagnosis of active tumor/cancer disease since the last visit |
new_medical_events |
| sct_86406008_1 |
New diagnosis of HIV infection since the last visit |
new_medical_events |
| sct_161663000 |
New transplant since the last visit |
new_medical_events |
| sct_399651003_25 |
Date of collection - Serology Tests |
serology_tests_serumplasma |
| sct_88667002 |
Has a sample for serology tests been collected? |
serology_tests_serumplasma |
| sct_78275009 |
Obstructive sleep apnoea since the last visitNo changes means stable disease |
new_medical_events |
| sct_414029004_other2 |
Other auto-inflammatory disease - specify |
new_medical_events |
| ln_62374_4_oth_v2 |
Other genome assembly version used as reference in imputation? |
human_genomics_edta_whole_blood |
| ncit_c164388_other |
Other genome reference sequence specifiedA published genetic sequence that is used as a reference sequence against which other sequences are compared. |
human_genomics_edta_whole_blood |
| sct_371039008_other |
Other thromboembolic event since the last visit No changes means stable disease |
new_medical_events |
| ncit_c45447_imput_oth_v2 |
Other value set for imputation methods - specify::The determination of the DNA sequence of an individual. |
human_genomics_edta_whole_blood |
| sct_56857008_2 |
Is a second serum neutralization (or pseudoneutralisation) test available? |
serology_tests_serumplasma |
| sct_75694006 |
Pancreatitis since the last visit No changes means stable disease |
new_medical_events |
| sct_56857008_4 |
Is fourth serum neutralization (or pseudoneutralisation) test available? |
serology_tests_serumplasma |
| sct_56857008_3 |
Is third serum neutralization (or pseudoneutralisation) test available? |
serology_tests_serumplasma |
| sct_49049000 |
Parkinson's disease since the last visit No changes means stable disease |
new_medical_events |
| ln_97155_6_received |
Did the patient receive a SARS-CoV-2 vaccine since the last visit? |
sarscov2_vaccination |
| no_2nddose |
Why the second dose was not administered? |
sarscov2_vaccination |
| other_no_2nddose |
Other - please, specify: |
sarscov2_vaccination |
| sct_1119350007_3rd |
Did the patient receive a mRNA vaccine as third dose? |
sarscov2_vaccination |
| sct_1119350007_4th |
Did the patient receive a mRNA vaccine as fourth dose? |
sarscov2_vaccination |
| seq_performer_1 |
Partner who performed the sequencing
|
human_genomics_edta_whole_blood |
| sct_1119350007_manuf_3 |
mRNA Vaccine manufacturer of the third dose |
sarscov2_vaccination |
| sct_1119350007_manuf_4 |
mRNA Vaccine manufacturer of the fourth dose |
sarscov2_vaccination |
| sct_1119350007_manuf_5 |
mRNA Vaccine manufacturer of the fifth dose |
sarscov2_vaccination |
| sct_1119350007_other_3 |
Other mRNA vaccine received as third dose |
sarscov2_vaccination |
| sct_1119350007_other_4 |
Other mRNA vaccine received as fourth dose |
sarscov2_vaccination |
| sct_1119350007_other_5 |
Other mRNA vaccine received as fifth dose |
sarscov2_vaccination |
| sct_1144997007 |
Did the patient receive a mRNA vaccine as first dose? |
sarscov2_vaccination |
| sct_1144997007_manuf |
mRNA Vaccine manufacturer of the first dose |
sarscov2_vaccination |
| sct_1144997007_other |
Other mRNA vaccine received as first dose |
sarscov2_vaccination |
| sct_1144998002 |
Did the patient receive a mRNA vaccine as second dose? |
sarscov2_vaccination |
| sct_1144998002_manuf |
mRNA Vaccine manufacturer of the second dose |
sarscov2_vaccination |
| sct_1144998002_other |
Other mRNA vaccine received as second dose |
sarscov2_vaccination |
| sct_399651003_5 |
Date of collection - Vaccination |
sarscov2_vaccination |
| sct_703503000_5 |
Data collector - Vaccination |
sarscov2_vaccination |
| sct_840534001 |
Did the patient receive a viral vector vaccine as first dose? |
sarscov2_vaccination |
| sct_840534001_2 |
Did the patient receive a viral vector vaccine as second dose? |
sarscov2_vaccination |
| sct_840534001_3rd |
Did the patient receive a viral vector vaccine as third dose? |
sarscov2_vaccination |
| sct_840534001_4th |
Did the patient receive a viral vector vaccine as fourth dose? |
sarscov2_vaccination |
| sct_840534001_5th |
Did the patient receive a viral vector vaccine as fifth dose? |
sarscov2_vaccination |
| sct_840534001_manuf |
Viral vector vaccine manufacturer of the first dose |
sarscov2_vaccination |
| sct_840534001_manuf_2 |
Viral vector vaccine manufacturer of the second dose |
sarscov2_vaccination |
| sct_840534001_manuf_3 |
Viral vector vaccine manufacturer of the third dose |
sarscov2_vaccination |
| sct_840534001_manuf_4 |
Viral vector vaccine manufacturer of the fourth dose |
sarscov2_vaccination |
| sct_840534001_manuf_5 |
Viral vector vaccine manufacturer of the fifth dose |
sarscov2_vaccination |
| sct_840534001_other |
Other viral vector vaccine received as first dose |
sarscov2_vaccination |
| sct_840534001_other_2 |
Other viral vector vaccine received as second dose |
sarscov2_vaccination |
| sct_840534001_other_3 |
Other viral vector vaccine received as third dose |
sarscov2_vaccination |
| sct_840534001_other_4 |
Other viral vector vaccine received as fourth dose |
sarscov2_vaccination |
| sct_840534001_other_5 |
Other viral vector vaccine received as fifth dose |
sarscov2_vaccination |
| vaccine_doses |
How many doses of the SARS-CoV-2 vaccine did the patient receive? |
sarscov2_vaccination |
| vaccine_fifth_dose |
Date of fifth dose received |
sarscov2_vaccination |
| vaccine_first_dose |
Date of first dose received |
sarscov2_vaccination |
| vaccine_fourth_dose |
Date of fourth dose received |
sarscov2_vaccination |
| vaccine_second_dose |
Date of second dose received |
sarscov2_vaccination |
| vaccine_third_dose |
Date of third dose received |
sarscov2_vaccination |
| sct_88667002_2_oth |
Please specify |
serology_tests_serumplasma |
| sct_3238004 |
Pericarditis since the last visitNo changes means stable disease |
new_medical_events |
| ncit_c180315 |
Platform Unit (PU)A data set that holds FLOWCELL_BARCODE, LANE, and SAMPLE_BARCODE. |
human_genomics_edta_whole_blood |
| sct_88667002_3_oth |
Please specify |
serology_tests_serumplasma |
| sct_88667002_oth |
Please specify |
serology_tests_serumplasma |
| sct_88667002_id |
Serology ORCHESTRA sample ID |
serology_tests_serumplasma |
| sct_88667002_date |
Serology tests - date of sample collection |
serology_tests_serumplasma |
| sct_60046008 |
Pleural effusion since the last visit No changes means stable disease |
new_medical_events |
| sct_36118008 |
Pneumothorax since the last visit No changes means stable disease |
new_medical_events |
| sct_289908002 |
Pregnancy since the last visit |
new_medical_events |
| sct_69322001 |
Psychotic disorder since the last visit No changes means stable disease |
new_medical_events |
| sct_6042001 |
Pulmonary aspergillosis since the last visit No changes means stable disease |
new_medical_events |
| sct_59282003 |
Pulmonary embolism since the last visit No changes means stable disease |
new_medical_events |
| sct_70995007 |
Pulmonary hypertension since the last visitNo changes means stable disease |
new_medical_events |
| ncit_c180313 |
Read Group Identifier (ID)The unique identifier for a read group. |
human_genomics_edta_whole_blood |
| ncit_c153362 |
Read sizeThe number of nucleotides successfully ordered from each side of a nucleic acid fragment obtained after the completion of a sequencing process. |
human_genomics_edta_whole_blood |
| sct_88667002_2_date |
Serology tests date |
serology_tests_serumplasma |
| sct_36485005 |
Restrictive lung disease since the last visitNo changes means stable disease |
new_medical_events |
| ncit_c180316 |
Sample (SM)The name of a sample sequenced in a read group. |
human_genomics_edta_whole_blood |
| sct_88667002_3_date |
Serology tests date |
serology_tests_serumplasma |
| sct_56857008 |
Serum neutralization (or pseudoneutralization) test available? |
serology_tests_serumplasma |
| ln_95411_5 |
Serum neutralization anti-SARS-CoV-2 (qualitative) |
serology_tests_serumplasma |
| ln_95411_5_2 |
Serum neutralization anti-SARS-CoV-2 (qualitative) |
serology_tests_serumplasma |
| ln_95411_5_3 |
Serum neutralization anti-SARS-CoV-2 (qualitative) |
serology_tests_serumplasma |
| ln_95411_5_4 |
Serum neutralization anti-SARS-CoV-2 (qualitative) |
serology_tests_serumplasma |
| ln_95410_7 |
Serum neutralization anti-SARS-CoV-2 (quantitative) |
serology_tests_serumplasma |
| ln_95410_7_2 |
Serum neutralization anti-SARS-CoV-2 (quantitative) |
serology_tests_serumplasma |
| ln_95410_7_3 |
Serum neutralization anti-SARS-CoV-2 (quantitative) |
serology_tests_serumplasma |
| ln_95410_7_4 |
Serum neutralization anti-SARS-CoV-2 (quantitative) |
serology_tests_serumplasma |
| ln_95410_7_unit |
Serum neutralization anti-SARS-CoV-2 (quantitative) unit |
serology_tests_serumplasma |
| ln_95410_7_unit_2 |
Serum neutralization anti-SARS-CoV-2 (quantitative) unit |
serology_tests_serumplasma |
| ln_95410_7_unit_3 |
Serum neutralization anti-SARS-CoV-2 (quantitative) unit |
serology_tests_serumplasma |
| ln_95410_7_unit_4 |
Serum neutralization anti-SARS-CoV-2 (quantitative) unit |
serology_tests_serumplasma |
| sct_56857008_2_date |
Serum neutralization test date |
serology_tests_serumplasma |
| sct_56857008_2_date_2 |
Serum neutralization test date |
serology_tests_serumplasma |
| sct_56857008_2_date_3 |
Serum neutralization test date |
serology_tests_serumplasma |
| sct_56857008_date |
Serum neutralization test date |
serology_tests_serumplasma |
| sct_88667002_2 |
Was another serology test performed? |
serology_tests_serumplasma |
| sct_88667002_3 |
Was another serology test performed? |
serology_tests_serumplasma |
| sct_68311008_ship |
Was the anti-IFN antibodies test performed locally or the sample shipped to WP6 laboratory? |
serology_tests_serumplasma |
| sct_88667002_ship |
Was the serology analysis performed locally or the sample shipped to WP6 laboratory? |
serology_tests_serumplasma |
| sct_56857008_ship |
Was the serum neutralization performed locally or the sample shipped to WP6 laboratory? |
serology_tests_serumplasma |
| sct_88667002_2_assay |
Which serology assay was used? |
serology_tests_serumplasma |
| sct_88667002_3_assay |
Which serology assay was used? |
serology_tests_serumplasma |
| sct_88667002_assay |
Which serology assay was used? |
serology_tests_serumplasma |
| sct_56857008_assay |
Which serum neutralization assay was used? |
serology_tests_serumplasma |
| sct_56857008_assay2 |
Which serum neutralization assay was used? |
serology_tests_serumplasma |
| sct_56857008_assay3 |
Which serum neutralization assay was used? |
serology_tests_serumplasma |
| sct_56857008_assay4 |
Which serum neutralization assay was used? |
serology_tests_serumplasma |
| sct_56857008_variant |
Which variant is used as reference? |
serology_tests_serumplasma |
| sct_56857008_variant2 |
Which variant is used as reference? |
serology_tests_serumplasma |
| sct_56857008_variant3 |
Which variant is used as reference? |
serology_tests_serumplasma |
| sct_56857008_variant4 |
Which variant is used as reference? |
serology_tests_serumplasma |
| sct_703503000_23 |
Data collector - Viral Variants |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_399651003_23 |
Date of collection - Viral Variants |
viral_variants_and_respiratory_microbiome_np_swab |
| ncit_c180324 |
GISAID Accession IDThe unique and permanent identifier for a virus, beginning with the letters EPI and followed by numbers, as proposed and maintained by GISAID. |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_96741_4 |
Has a sample for viral variants or respiratory microbiome analysis been collected? |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_96896_6 |
Nextclade result |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_96896_6_db |
Pangolin database version |
viral_variants_and_respiratory_microbiome_np_swab |
| ncit_c180312 |
Pangolin LineageThe number of nucleotides inserted into a sequencing vector. |
viral_variants_and_respiratory_microbiome_np_swab |
| new_seq_criteria |
Criteria to apply the socio-economic questionnaire |
socioeconomic_questionnaire |
| sct_105421008_quest |
What is the highest level of education that you have achieved to date? |
socioeconomic_questionnaire |
| sct_125680007 |
What is your current marital status? |
socioeconomic_questionnaire |
| sct_399651003_20 |
Date of collection - Socio-economic Questionnaire |
socioeconomic_questionnaire |
| sct_703503000_20 |
Data collector - Socio-economic Questionnaire |
socioeconomic_questionnaire |
| soc_econ_10 |
What is your current total monthly household net income (after taxes)? Net income refers to everyone who lives in your household and contributes to the household budget. |
socioeconomic_questionnaire |
| soc_econ_11 |
Since the beginning of the pandemic (February/March 2020), have you had financial or liquidity problems (such as problems paying rent, school fees, mortgage, utility bills, etc.)? |
socioeconomic_questionnaire |
| soc_econ_12 |
Since the beginning of the pandemic (February/March 2020), have you received any financial or material aid (e.g. public assistance, cash-transfers, items from food bank, etc.)? |
socioeconomic_questionnaire |
| soc_econ_13 |
How often have you recently looked for information on COVID19 on the internet, in newspapers, on television, radio, within social networks, and so on?COVID19-related information includes data on efficacy and safety of vaccines, development of vaccination plans in your country, number of new cases, etc. |
socioeconomic_questionnaire |
| soc_econ_14 |
On a theoretical scale from 0 to 10, what do you think is your current risk of infection/re-infection? |
socioeconomic_questionnaire |
| soc_econ_15 |
On a theoretical scale from 0 to 10, what do you think is your current risk that, in case of infection/re-infection, you will experience severe complications or even death? |
socioeconomic_questionnaire |
| soc_econ_16_a |
How often do you wash your hands with hand-soap or hydro-alcoholic solutions? |
socioeconomic_questionnaire |
| soc_econ_16_b |
Do you keep a distance of at least 2 meters from others? |
socioeconomic_questionnaire |
| soc_econ_16_c |
Do you stay at home to avoid social contacts or avoid gatherings with friends and relatives outside of your household/support bubble? |
socioeconomic_questionnaire |
| soc_econ_16_e |
Do you wear a face mask in public? |
socioeconomic_questionnaire |
| soc_econ_18 |
Have you been offered a vaccine by the public health system? |
socioeconomic_questionnaire |
| soc_econ_19 |
Have you accepted or will you accept to be vaccinated once you get offered a vaccine? |
socioeconomic_questionnaire |
| soc_econ_4 |
What is the total number of household members? |
socioeconomic_questionnaire |
| soc_econ_5 |
What is the number of household members below the age of 14? |
socioeconomic_questionnaire |
| soc_econ_6a |
I have experienced cancellations of routine doctor's visits and/or check-ups |
socioeconomic_questionnaire |
| soc_econ_6b |
I have experienced postponements of routine doctor's visits and/or check-ups |
socioeconomic_questionnaire |
| soc_econ_7a |
I have had problems accessing medication |
socioeconomic_questionnaire |
| soc_econ_7b |
Treatment sessions were postponed by doctor or patient |
socioeconomic_questionnaire |
| soc_econ_7c |
Treatment sessions were cancelled by doctor or patient |
socioeconomic_questionnaire |
| soc_econ_8 |
Which one of the following best describes your current employment situation? |
socioeconomic_questionnaire |
| soc_econ_9 |
How many total hours a week do you work on average? |
socioeconomic_questionnaire |
| soc_econ_date |
Socio-economic questionnaire completion date |
socioeconomic_questionnaire |
| soc_econ_next_10 |
Over the last 12 months, have you received any financial or material aid (e.g. public assistance, cash-transfers, items from food bank, etc.)? |
socioeconomic_questionnaire |
| soc_econ_next_18 |
Why did/would you not accept the vaccine? |
socioeconomic_questionnaire |
| soc_econ_next_4_a |
I have experienced cancellations of routine doctor's visits and/or check- |
socioeconomic_questionnaire |
| soc_econ_next_4_b |
I have experienced postponements of routine doctor's visits and/or check-ups |
socioeconomic_questionnaire |
| soc_econ_next_5b |
I have had problems accessing medication |
socioeconomic_questionnaire |
| soc_econ_next_5c |
Treatment sessions were postponed by doctor or patient |
socioeconomic_questionnaire |
| soc_econ_next_5d |
Treatment sessions were cancelled by doctor or patient |
socioeconomic_questionnaire |
| soc_econ_next_9 |
Over the last 12 months, have you had financial or liquidity problems (such as problems paying rent, school fees, mortgage, utility bills, etc.)? |
socioeconomic_questionnaire |
| sct_86553008 |
Immunosuppressive therapy: |
treatment |
| sct_86553008_specify |
Immunosuppressive therapy - please, specify: |
treatment |
| sct_86198006 |
Influenza |
vaccination |
| ln_94309_2_v2manuf |
SARS-CoV-2 PCR CT manufacturer |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_3981005_oth |
SARS-CoV-2 PCR CT other gene specify |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_230690007 |
Stroke since the last visit No changes means stable disease |
new_medical_events |
| ln_94309_2_v2_manuf_oth |
SARS-CoV-2 PCR CT other manufacturer specify |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_94309_2_v2 |
SARS-CoV-2 PCR CT test result (global) |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_161663000_type_fup |
Transplant description |
new_medical_events |
| ln_96763_8 |
SARS-CoV-2 PCR CT test result E |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_56717001_1 |
Tuberculosis co-infection since the last visit |
new_medical_events |
| ln_81304_8_v2 |
Variant analysis method used? |
human_genomics_edta_whole_blood |
| ln_94316_7 |
SARS-CoV-2 PCR CT test result N |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_871560001_n2_ql |
SARS-CoV-2 PCR CT test result N2 |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_97098_8 |
SARS-CoV-2 PCR CT test result NSP2 |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_94639_2 |
SARS-CoV-2 PCR CT test result ORF1ab |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_3981005_res |
SARS-CoV-2 PCR CT test result other specify |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_86206_0_86205_2_ship |
Was the human genomics analysis performed locally or the samples shipped to WP6 laboratory? |
human_genomics_edta_whole_blood |
| ln_94641_8 |
SARS-CoV-2 PCR CT test result S |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_96764_6 |
SARS-CoV-2 PCR CT value - E |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_94510_5 |
SARS-CoV-2 PCR CT value - N |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_871560001_n2_qn |
SARS-CoV-2 PCR CT value - N2 |
viral_variants_and_respiratory_microbiome_np_swab |
| ncit_c45447_imput_v2 |
Which imputation method was used?::The determination of the DNA sequence of an individual. |
human_genomics_edta_whole_blood |
| ln_97098_8_ct |
SARS-CoV-2 PCR CT value - NSP2 |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_94511_3 |
SARS-CoV-2 PCR CT value - ORF1ab |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_3981005_ct |
SARS-CoV-2 PCR CT value - other specify |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_94643_4 |
SARS-CoV-2 PCR CT value - S |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_3981005 |
SARS-CoV-2 PCR gene detection and corresponding CT values |
viral_variants_and_respiratory_microbiome_np_swab |
| seq_performer |
Sequencing performed by |
viral_variants_and_respiratory_microbiome_np_swab |
| seq_performer_other |
Sequencing performed by, if "other" selected, specify |
viral_variants_and_respiratory_microbiome_np_swab |
| ncit_c172274_1 |
Sequencing technology The name of the technology platform used to perform nucleic acid sequencing. |
viral_variants_and_respiratory_microbiome_np_swab |
| sct_258048005_viral |
To which analysis the sample was collected? |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_96741_4_date |
Viral variants or respiratory microbiome analysis - date of sample collection |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_96741_4_id |
Viral variants or respiratory microbiome analysis ORCHESTRA sample ID |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_86205_2_86206_0 |
Whole exome or whole genome sequencing performed? |
human_genomics_edta_whole_blood |
| ln_96741_4_ship |
Was the viral variants analysis performed locally or the sample shipped to WP6 laboratory? |
viral_variants_and_respiratory_microbiome_np_swab |
| ln_1920_8 |
AST (U/L): |
visit |
| ln_2532_0 |
Lactate dehydrogenase (LDH)LP15033-1 Lactate dehydrogenase Lactate dehydrogenase (LDH) is an enzyme (EC 1.1.1.27) present in a wide variety of organisms, including plants and animals. It catalyses the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. As it can also catalyze the oxidation of hydroxybutyrate, it is occasionally called hydroxybutyrate dehydrogenase (HBD). |
visit |
| ln_2532_0_avail |
Lactate dehydrogenase (LDH) available |
visit |
| ln_2532_0_date |
Lactate dehydrogenase (LDH) date |
visit |
| ln_2532_0_unit |
LDH unit |
visit |
| ln_26464_8 |
Leukocytes |
visit |
| ln_26464_8_avail |
Leukocytes available |
visit |
| ln_26464_8_date |
Leukocytes date |
visit |
| ln_26464_8_unit |
Leukocytes unit |
visit |
| ln_34970_4 |
Ultrasound date |
visit |
| ln_592600_7187_303503 |
Hemoglobin |
visit |
| ln_592600_7187_303503_avai |
Hemoglobin available |
visit |
| ln_592600_7187_303503_date |
Hemoglobin date |
visit |
| ln_76625_3 |
ALT (U/L): |
visit |
| ln592600_7187_303503_unit |
Hemoglobin unit |
visit |
| sct_289908002_1 |
Current pregnancy? |
visit |
| sct_840643003 |
Date last visit: |
visit |